<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia - Paul, M - 2013 | Cochrane Library</title> <meta content="Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia - Paul, M - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003038.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia - Paul, M - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003038.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003038.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia" name="citation_title"/> <meta content="Mical Paul" name="citation_author"/> <meta content="Rambam Health Care Campus" name="citation_author_institution"/> <meta content="paulm@post.tau.ac.il" name="citation_author_email"/> <meta content="Yaakov Dickstein" name="citation_author"/> <meta content="Rambam Health Care Center" name="citation_author_institution"/> <meta content="Agata Schlesinger" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Simona Grozinsky‐Glasberg" name="citation_author"/> <meta content="Dept of Medicine, Hadassah‐Hebrew University Medical Center" name="citation_author_institution"/> <meta content="Karla Soares‐Weiser" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Leonard Leibovici" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD003038.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/06/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003038.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003038.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003038.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aminoglycosides [adverse effects, *therapeutic use]; Anti‐Bacterial Agents [*therapeutic use]; Cause of Death; Combined Modality Therapy [adverse effects, methods]; Neoplasms [*complications]; Neutropenia [*drug therapy, mortality]; Randomized Controlled Trials as Topic; beta‐Lactams [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003038.pub2&amp;doi=10.1002/14651858.CD003038.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003038\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003038\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003038.pub2",title:"Beta\\u2010lactam versus beta\\u2010lactam\\u2010aminoglycoside combination therapy in cancer patients with neutropenia",firstPublishedDate:"Jun 29, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003038.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003038.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003038.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003038.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003038.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003038.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003038.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003038.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003038.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003038.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3152 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003038.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-sec-0064"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-sec-0031"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-sec-0032"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-sec-0063"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/appendices#CD003038-sec-0069"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/table_n/CD003038StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/table_n/CD003038StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information#CD003038-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Mical Paul</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information#CD003038-cr-0003">Yaakov Dickstein</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information#CD003038-cr-0004">Agata Schlesinger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information#CD003038-cr-0005">Simona Grozinsky‐Glasberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information#CD003038-cr-0006">Karla Soares‐Weiser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information#CD003038-cr-0007">Leonard Leibovici</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information/en#CD003038-sec-0076">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 June 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003038.pub2">https://doi.org/10.1002/14651858.CD003038.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003038-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003038-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003038-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003038-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003038-abs-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003038-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003038-abs-0001" lang="en"> <section id="CD003038-sec-0001"> <h3 class="title" id="CD003038-sec-0001">Background</h3> <p>Continued controversy surrounds the optimal empirical treatment for febrile neutropenia. New broad‐spectrum beta‐lactams have been introduced as single treatment, and classically, a combination of a beta‐lactam with an aminoglycoside has been used. </p> </section> <section id="CD003038-sec-0002"> <h3 class="title" id="CD003038-sec-0002">Objectives</h3> <p>To compare beta‐lactam monotherapy versus beta‐lactam‐aminoglycoside combination therapy for cancer patients with fever and neutropenia. </p> </section> <section id="CD003038-sec-0003"> <h3 class="title" id="CD003038-sec-0003">Search methods</h3> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>, Issue 7, 2012), LILACS (August 2012), MEDLINE and EMBASE (August 2012) and the Database of Abstracts of Reviews of Effects (DARE) (Issue 3, 2012). We scanned references of all included studies and pertinent reviews and contacted the first author of each included trial, as well as the pharmaceutical companies. </p> </section> <section id="CD003038-sec-0004"> <h3 class="title" id="CD003038-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing any beta‐lactam antibiotic monotherapy with any combination of a beta‐lactam and an aminoglycoside antibiotic, for the initial empirical treatment of febrile neutropenic cancer patients. All cause mortality was the primary outcome assessed. </p> </section> <section id="CD003038-sec-0005"> <h3 class="title" id="CD003038-sec-0005">Data collection and analysis</h3> <p>Data concerning all cause mortality, infection related mortality, treatment failure (including treatment modifications), super‐infections, adverse effects and study quality measures were extracted independently by two review authors. Risk ratios (RRs) with their 95% confidence intervals (CIs) were estimated. Outcomes were extracted by intention‐to‐treat (ITT) analysis whenever possible. Individual domains of risk of bias were examined through sensitivity analyses. Published data were complemented by correspondence with authors. </p> </section> <section id="CD003038-sec-0006"> <h3 class="title" id="CD003038-sec-0006">Main results</h3> <p>Seventy‐one trials published between 1983 and 2012 were included. All cause mortality was lower with monotherapy (RR 0.87, 95% CI 0.75 to 1.02, without statistical significance). Results were similar for trials comparing the same beta‐lactam in both trial arms (11 trials, 1718 episodes; RR 0.74, 95% CI 0.53 to 1.06) and for trials comparing different beta‐lactams－usually a broad‐spectrum beta‐lactam compared with a narrower‐spectrum beta‐lactam combined with an aminoglycoside (33 trials, 5468 episodes; RR 0.91, 95% CI 0.77 to 1.09). Infection related mortality was significantly lower with monotherapy (RR 0.80, 95% CI 0.64 to 0.99). Treatment failure was significantly more frequent with monotherapy in trials comparing the same beta‐lactam (16 trials, 2833 episodes; RR 1.11, 95% CI 1.02 to 1.20), and was significantly more frequent with combination therapy in trials comparing different beta‐lactams (55 trials, 7736 episodes; RR 0.92, 95% CI 0.88 to 0.97). Bacterial super‐infections occurred with equal frequency, and fungal super‐infections were more common with combination therapy. Adverse events were more frequent with combination therapy (numbers needed to harm 4; 95% CI 4 to 5). Specifically, the difference with regard to nephrotoxicity was highly significant. Adequate trial methods were associated with a larger effect estimate for mortality and smaller effect estimates for failure. Nearly all trials were open‐label. No correlation was noted between mortality and failure rates and these trials. </p> </section> <section id="CD003038-sec-0007"> <h3 class="title" id="CD003038-sec-0007">Authors' conclusions</h3> <p>Beta‐lactam monotherapy is advantageous compared with beta‐lactam‐aminoglycoside combination therapy with regard to survival, adverse events and fungal super‐infections. Treatment failure should not be regarded as the primary outcome in open‐label trials, as it reflects mainly treatment modifications. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003038-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003038-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003038-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003038-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003038-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003038-abs-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003038-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003038-abs-0003" lang="en"> <h3>Cancer patients with fever and suspected infection can be treated with a single 'new‐generation' beta‐lactam antibiotic </h3> <p>Cancer chemotherapy or bone marrow transplantation disrupts the immune system, exposing patients to severe infection. The major sign of infection is fever, and the hallmark of damaged immune defences is a decreased white blood cell count. Patients have usually been treated with a combination of two different classes of antibiotics. Evidence shows that treatment with a new single drug (monotherapy), belonging to the beta‐lactam class of antibiotics, is associated with better outcomes. Survival is improved when single‐drug therapy is used, and side effects, mainly damage to the kidneys, are more frequent with combination therapy. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003038-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003038-sec-0064"></div> <h3 class="title" id="CD003038-sec-0065">Implications for practice</h3> <section id="CD003038-sec-0065"> <p>Monotherapy can be regarded as the standard of care for the empirical treatment of febrile neutropenic patients. The addition of an aminoglycoside does not improve survival. On the contrary, it is associated with significant morbidity incurred mainly through aminoglycoside‐associated nephrotoxicity. </p> <p>The monotherapies assessed in recent years have included imipenem, meropenem, ceftazidime, piperacillin‐tazobactam and cefepime. These beta‐lactams have also been assessed in head‐to‐head trials comparing different monotherapies and have shown similar efficacies, but for cefepime this was associated with increased all cause mortality (<a href="./references#CD003038-bbs2-0119" title="PaulM , YahavD , FraserA , LeiboviciL . Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta‐analysis of randomized controlled trials. Antimicrobial Agents &amp; Chemotherapy2006;57(2):176‐89. ">Paul 2006</a>). Thus, individual centres should select the best matching monotherapy according to local epidemiology and susceptibility patterns. </p> <p>RCTs do not support an advantage of combination therapy for <i>Pseudomonas aeruginosa</i> infection and other more severely ill patient subgroups. However the paucity of data precludes firm conclusions regarding these patient subgroups. </p> </section> <h3 class="title" id="CD003038-sec-0066">Implications for research</h3> <section id="CD003038-sec-0066"> <p>Assessment of new beta‐lactams for febrile neutropenia should not be performed by comparison with a narrower‐spectrum beta‐lactam combined with an aminoglycoside. The results of these trials are uniformly unfavourable for patients. Assessment of new beta‐lactam monotherapies should be performed by comparison with established monotherapies for febrile neutropenia. This design can and does show the advantages and disadvantages of specific beta‐lactams (<a href="./references#CD003038-bbs2-0119" title="PaulM , YahavD , FraserA , LeiboviciL . Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta‐analysis of randomized controlled trials. Antimicrobial Agents &amp; Chemotherapy2006;57(2):176‐89. ">Paul 2006</a>). </p> <p>The need for further trials assessing the addition of an aminoglycoside to the same beta‐lactam is doubtful given the results of our review, spanning more than two decades of clinical trials in febrile neutropenia and without a change in RRs throughout the years. We can foresee such a need if a reduction in aminoglycoside‐related adverse effects is expected, or if new data will point toward drug combinations with a marked synergistic effect－much greater than that observed in current studies. Trials targeting specific patient subgroups, such as those with severe sepsis and septic shock, documented <i>Pseudomonas aeruginosa</i> infection, etc. are warranted. </p> <p>Future trials should report all cause mortality. The primary outcome used in these studies should be re‐defined because with current definitions, no correlation can be noted between failure and the ultimate outcome: survival. This outcome should be defined in a consensus statement and applied universally to permit comparisons and compilation of different studies. The unit of randomisation should be the patient－not the episode. If recurrent episodes are allowed, results for the first randomisation of each patient should be reported separately, or the analysis should be adjusted to the clustering effect of patient episodes. Length of follow‐up should be uniform and should be determined before the study is begun. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003038-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003038-sec-0029"></div> <div class="table" id="CD003038-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">beta‐lactam monotherapy compared to beta‐lactam‐aminoglycoside combination therapy for Febrile neutropenic cancer patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐lactam monotherapy compared with beta‐lactam‐aminoglycoside combination therapy for febrile neutropenic cancer patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> febrile neutropenic cancer patients.<br/> <b>Settings:</b> <br/> <b>Intervention:</b> beta‐lactam monotherapy.<br/> <b>Comparison:</b> beta‐lactam‐aminoglycoside combination therapy. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Beta‐lactam‐aminoglycoside combination therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Beta‐lactam monotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.87</b> <br/> (0.75 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7186<br/> (44 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> <br/> (62 to 85) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> <br/> (51 to 69) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Any nephrotoxicity ‐ Ag dosing regimen (Copy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> <br/> (0.35 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6608<br/> (39 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (20 to 33) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (10 to 17) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure ‐ same beta‐lactam</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.11</b> <br/> (1.02 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2833<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>449 per 1000</b> <br/> (413 to 485) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>398 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>442 per 1000</b> <br/> (406 to 478) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure ‐ different beta‐lactam</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.88 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7736<br/> (55 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>426 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>392 per 1000</b> <br/> (375 to 413) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>432 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>397 per 1000</b> <br/> (380 to 419) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Outcome determined mainly by treatment modifications. Poor correlation with all cause mortality, the ultimate target of treating cancer patients.<br/> <sup>2</sup> Differences decreased with low risk of bias regarding allocation concealment.<br/> <sup>3</sup> Differences in effects between published and unpublished trials.<br/> <sup>4</sup> No explanation was provided.&amp;&amp; </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003038-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003038-sec-0030"></div> <p>Cancer patients are prone to infection. Low blood cell count (neutropenia) and disruption of normal barriers to infection, such as skin and mucous membranes, are caused by chemotherapy or underlying malignancy. Both disrupt the normal immune response and predispose patients to infection (<a href="./references#CD003038-bbs2-0098" title="BodeyGP , BuckleyM , SatheYS , FreireichEJ . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine1966;64(2):328‐40. ">Bodey 1966</a>). Pathogens implicated in these infections are Gram‐negative bacteria, including <i>Pseudomonas aeruginosa</i>, Gram‐positive bacteria and fungi (<a href="./references#CD003038-bbs2-0100" title="ChowJW , FineMJ , ShlaesDM , QuinnJP , HooperDC , JohnsonMP , et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Annals of Internal Medicine1991;115(8):585‐90. ">Chow 1991</a>; <a href="./references#CD003038-bbs2-0110" title="HughesWT , ArmstrongD , BodeyGP , BrownAE , EdwardsJE , FeldR , et al. From the Infectious Diseases Society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases1997;25(3):551‐73. ">Hughes 1997</a>). The considerable morbidity and mortality associated with these infections in neutropenic patients led to the routine use of empirical antibiotic treatment, which is given upon suspicion of infection (e.g. fever), before the causative pathogen/s or their susceptibilities are identified (<a href="./references#CD003038-bbs2-0110" title="HughesWT , ArmstrongD , BodeyGP , BrownAE , EdwardsJE , FeldR , et al. From the Infectious Diseases Society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases1997;25(3):551‐73. ">Hughes 1997</a>; <a href="./references#CD003038-bbs2-0123" title="SchimpffSC . Empiric antibiotic therapy for granulocytopenic cancer patients. American Journal of Medicine1986;80:Suppl 5C:13‐20. ">Schimpff 1986</a>). </p> <p>Initial effective empirical treatment for patients with fever and neutropenia consisted of combinations of antibiotics, including double beta‐lactam regimens and, more recently, aminoglycoside‐beta‐lactam combinations (<a href="./references#CD003038-bbs2-0109" title="HughesWT , ArmstrongD , BodeyGP , FeldR , MandellGL , MeyersJD , et al. From the Infectious Diseases Society of America: guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infection1990;161(3):381‐96. ">Hughes 1990</a>; <a href="./references#CD003038-bbs2-0110" title="HughesWT , ArmstrongD , BodeyGP , BrownAE , EdwardsJE , FeldR , et al. From the Infectious Diseases Society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases1997;25(3):551‐73. ">Hughes 1997</a>; <a href="./references#CD003038-bbs2-0122" title="SchimpffS , SatterleeW , YoungVM , SerpickA . Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. New England Journal of Medicine1971;284(19):1061‐5. ">Schimpff 1971</a>). In the 1980s, third‐generation cephalosporins and carbapenems having bactericidal activity against Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> and many Gram‐positive organisms became available, making monotherapy a reasonable alternative to combination therapy. Neither combination therapy nor monotherapy provides full coverage for the spectrum of infections encountered among neutropenic patients. Notably, resistant Gram‐positive bacteria and fungi are left untreated. Nevertheless, current guidelines recommend beta‐lactam monotherapy in clinically stable patients (<a href="./references#CD003038-bbs2-0104" title="FreifeldAG , BowEJ , SepkowitzKA , BoeckhMJ , ItoJI , MullenCA , et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases2011;52(4):e56‐93. ">Freifeld 2011</a>; <a href="./references#CD003038-bbs2-0126" title="TamCS , O'ReillyM , AndresenD , LingaratnamS , KellyA , BurburyK , et al. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. Internal Medicine Journal2011;41(1b):90‐101. ">Tam 2011</a>). </p> <p>An evident advantage of combination therapy over monotherapy is the higher probability that the infecting pathogen will be covered by at least one of the components of the regimen. Furthermore, the interaction between two antibiotics may be synergistic, resulting in enhanced bacterial kill activity compared with the additive activities of the antibiotics when assessed separately (<a href="./references#CD003038-bbs2-0105" title="GiamarellouH , ZissisP , TagariG , BouzosJ . In vitro synergistic activities of aminoglycosides and new beta lactams against multiresistant Pseudomonas aeruginosa . Antimicrobial Agents and Chemotherapy1984;25(4):534‐6. ">Giamarellou 1984</a>; <a href="./references#CD003038-bbs2-0106" title="GiamarellouH . Aminoglycosides plus beta lactams against gram negative organisms: evaluation of in vitro synergy and chemical interactions. American Journal of Medicine1986;80:Suppl 6B:126‐37. ">Giamarellou 1986</a>; <a href="./references#CD003038-bbs2-0111" title="KlasterskyJ , Meunier‐CarpentierF , PrevostJM , StaquetM . Synergism between amikacin and cefazolin against Klebsiella . Journal of Infectious Diseases1976;134(3):271‐6. ">Klastersky 1976</a>; <a href="./references#CD003038-bbs2-0112" title="KlasterskyJ , ZinnerSH . Synergistic combinations of antibiotics in gram negative bacillary infections. Review of Infectious Diseases1982;4(2):294‐301. ">Klastersky 1982</a>). Finally, use of combination therapy has been claimed to suppress the emergence of resistant subpopulations of bacteria (<a href="./references#CD003038-bbs2-0096" title="AllanJD , MoelleringRCJr . Management of infections caused by gram negative bacilli: the role of antimicrobial combinations. Reviews of Infectious Diseases1985;7:Suppl 4:S559‐71. ">Allan 1985</a>; <a href="./references#CD003038-bbs2-0116" title="MilatovicD , BravenyI . Development of resistance during antibiotic therapy. European Journal of Clinical Microbiology and Infectious Diseases1987;6(3):234‐44. ">Milatovic 1987</a>; <a href="./references#CD003038-bbs2-0128" title="WadeJC . Antibiotic therapy for the febrile granulopenic cancer patient: combination therapy versus monotherapy. Review of Infectious Diseases1989;11:Suppl 7:S1572‐81. ">Wade 1989</a>). On the other hand, benefits of monotherapy may include a lower probability of adverse effects and narrower‐spectrum treatment, possibly reducing the chance of developing a super‐infection with resistant bacteria (<a href="./references#CD003038-bbs2-0129" title="WeisteinL . Gram negative bacterial infections: a look at the past, a view of the present, and a glance at the future. Review of Infectious Diseases1985;7:Suppl 4:S538‐44. ">Weistein 1985</a>). Adverse effects may be related to administration of aminoglycosides per se (e.g. nephrotoxicity) or to interactions between antibiotic and underlying disease and/or other drugs. Neutropaenic participants not responding to the initial antibiotic regimen will be given modified treatment, which usually includes vancomycin to cover resistant Gram‐positive bacteria and/or amphotericin‐based preparations or azoles to treat fungal infection (<a href="./references#CD003038-bbs2-0110" title="HughesWT , ArmstrongD , BodeyGP , BrownAE , EdwardsJE , FeldR , et al. From the Infectious Diseases Society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases1997;25(3):551‐73. ">Hughes 1997</a>), thus increasing the chance for adverse events and drug interactions. </p> <p>Although neutropenia itself is the single most important risk factor for infection, other factors can alter the risk. The probability and severity of infection are inversely proportional to the absolute neutrophil count, and patients with neutrophil counts below 100/mm³ are at highest risk for severe infection (<a href="./references#CD003038-bbs2-0098" title="BodeyGP , BuckleyM , SatheYS , FreireichEJ . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine1966;64(2):328‐40. ">Bodey 1966</a>; <a href="./references#CD003038-bbs2-0123" title="SchimpffSC . Empiric antibiotic therapy for granulocytopenic cancer patients. American Journal of Medicine1986;80:Suppl 5C:13‐20. ">Schimpff 1986</a>). Underlying malignancy may affect outcome. Patients with acute leukaemia and other haematological malignancies have a worse prognosis than solid tumour patients (<a href="./references#CD003038-bbs2-0062" title="RolstonKV , BerkeyP , BodeyGP , AnaissieEJ , KhardoriNM , JoshiJH , et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Archives of Internal Medicine1992;152(2):283‐91. ">Rolston 1992</a>; <a href="./references#CD003038-bbs2-0121" title="RossiniF , PioltelliP , MingozziS , BreganiR , ViganoF , BolisS , et al. Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors. Supportive Care in Cancer1994;2(4):259‐65. ">Rossini 1994</a>; <a href="./references#CD003038-bbs2-0125" title="TalcottJA , SiegelRD , FinbergR , GoldmanL . Risk assessment in cancer patients with fever and neutropenia: a prospective, two‐center validation of a prediction rule. Journal of Clinical Oncology1992;10(2):316‐22. ">Talcott 1992</a>). The severity and nature of the infection (e.g. bacteraemia, Gram‐positive and <i>Pseudomonas aeruginosa</i> infections, resistant organisms) as well as the patient's age may underlie heterogeneity (<a href="./references#CD003038-bbs2-0103" title="EltingLS , RubensteinEB , RolstonKV , BodeyGP . Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clinical Infectious Diseases1997;25(2):247‐59. ">Elting 1997</a>; <a href="./references#CD003038-bbs2-0107" title="HannI , ViscoliC , PaesmansM , GayaH , GlauserM . A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). British Journal of Haematology1997;99(3):580‐8. ">Hann 1997</a>; <a href="./references#CD003038-bbs2-0062" title="RolstonKV , BerkeyP , BodeyGP , AnaissieEJ , KhardoriNM , JoshiJH , et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Archives of Internal Medicine1992;152(2):283‐91. ">Rolston 1992</a>). More recent guidelines for empirical treatment of febrile neutropenia have emphasized the importance of risk stratification, both for deciding on the setting of therapy (out‐patient versus hospitalisation) and for choosing among empirical antibiotics (monotherapy versus combination therapy) (<a href="./references#CD003038-bbs2-0104" title="FreifeldAG , BowEJ , SepkowitzKA , BoeckhMJ , ItoJI , MullenCA , et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases2011;52(4):e56‐93. ">Freifeld 2011;</a><a href="./references#CD003038-bbs2-0126" title="TamCS , O'ReillyM , AndresenD , LingaratnamS , KellyA , BurburyK , et al. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. Internal Medicine Journal2011;41(1b):90‐101. ">Tam 2011</a>). </p> <p>We undertook this systematic review to assess the evidence for combination therapy versus monotherapy in patients with febrile neutropenia in clinical trials. In 2002, the first version of this review was published. Results showed no advantage of combination therapy with regard to all cause mortality, the primary outcome assessed and an increased rate of nephrotoxicity with the combined regimen. Most trials compared a broad‐spectrum beta‐lactam with an older beta‐lactam combined with an aminoglycoside; however comparisons performed to directly assess our research question, that is, trials comparing the same beta‐lactam with or without an aminoglycoside, were rare. We called for further studies assessing directly the clinical implications of synergism, and further trials comparing different beta‐lactams were discouraged in our recommendations (<a href="./references#CD003038-bbs2-0117" title="PaulM , Soares‐WeiserK , LeiboviciL . Beta lactam monotherapy versus beta lactam‐aminoglycoside combination therapy for fever with neutropenia: systematic review and meta‐analysis. BMJ2003;326:1111. ">Paul 2003</a>). In 2008 we updated our systematic review with new evidence that had accumulated since publication of the first version of our review; no significant differences were presented in terms of outcomes or subsequent recommendations. At present we are undertaking to update the review to include new evidence that has accumulated since the previous version. </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003038-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003038-sec-0031"></div> <p>To compare the effectiveness of beta‐lactam monotherapy versus that of beta‐lactam‐aminoglycoside combination therapy in febrile neutropenic cancer patients. In addition, to compare the effectiveness of the two treatment modalities in the following subgroups of neutropenic participants: </p> <p> <ul id="CD003038-list-0001"> <li> <p>Participants with an absolute neutrophil count of less than 100/mm³</p> </li> <li> <p>Participants with microbiologically documented infection</p> </li> <li> <p>Participants with documented <i>Pseudomonas aeruginosa</i> infection </p> </li> <li> <p>Bacteraemic participants</p> </li> <li> <p>Participants with an underlying haematological malignancy or bone marrow transplantation</p> </li> </ul> </p> <p>The following hypotheses were tested for the comparison between participants treated with beta‐lactam monotherapy and those treated with beta‐lactam‐aminoglycoside combination therapy: </p> <p> <ul id="CD003038-list-0002"> <li> <p>There is no difference in the number of deaths in febrile neutropenic patients</p> </li> <li> <p>There is no difference in the number of deaths in the above subgroups of febrile neutropenic patients </p> </li> <li> <p>There is no difference in the number of treatment failures in all febrile neutropenic patients and in the defined subgroups </p> </li> <li> <p>There is no difference in the number and severity of adverse effects among all patients</p> </li> <li> <p>There is no difference in the rate of resistant colonisation and super‐infection among all neutropenic patients </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003038-sec-0032" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003038-sec-0032"></div> <section id="CD003038-sec-0033"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003038-sec-0034"> <h4 class="title">Types of studies</h4> <p>Randomised or quasi‐randomised trials comparing any beta‐lactam antibiotic monotherapy with any combination of a beta‐lactam and an aminoglycoside antibiotic, for the treatment of febrile neutropenia in cancer patients. Allocation to these regimens had to occur initially, before administration of any other antibiotics for the specific febrile episode and, empirically, before detection of pathogen/s or their susceptibilities. </p> <p>Trials with randomly assigned participants with microbiologically documented infection (e.g. <i>Pseudomonas aeruginosa</i> infection, Gram‐negative bacteraemia) were excluded, as were trials comparing short versus long courses of aminoglycoside treatment, because in both cases randomisation to combination treatment versus monotherapy did not occur empirically (referred to as semi‐empirical studies). </p> </section> <section id="CD003038-sec-0035"> <h4 class="title">Types of participants</h4> <p>Febrile cancer patients with neutropenia, as defined in the study, induced by chemotherapy or bone marrow transplantation. Neonates and preterm babies were excluded. </p> </section> <section id="CD003038-sec-0036"> <h4 class="title">Types of interventions</h4> <p>The following antibiotic regimens were compared:</p> <p> <ul id="CD003038-list-0003"> <li> <p>Intravenous beta‐lactam antibiotic given as monotherapy, including:</p> </li> </ul> <ul class="plain" id="CD003038-list-0004"> <li> <ul id="CD003038-list-0005"> <li> <p>Antipseudomonal carboxy‐penicillins or ureido‐penicillins ± beta‐lactamase inhibitor (piperacillin, piperacillin/clavulanate, ticarcillin‐clavulanate, azlocilin, mezlocillin) </p> </li> <li> <p>Cephalosporins (ceftazidime, ceftriaxone, cefoperazone, cefoxitin, cefuroxime, cefepime, cefpiramide) </p> </li> <li> <p>Carbapenems (imipenem/cilastatin, meropenem)</p> </li> </ul> </li> </ul> </p> <p>Studies comparing the same beta‐lactam, with the addition of an aminoglycoside to one arm ('same beta‐lactam'), were analysed separately from studies comparing different beta‐lactams ('different beta‐lactam'). </p> <p> <ul id="CD003038-list-0006"> <li> <p>Combination duotherapy of an intravenous beta‐lactam antibiotic (as specified) with one of the following aminoglycosides given intravenously: </p> </li> </ul> <ul class="plain" id="CD003038-list-0007"> <li> <ul id="CD003038-list-0008"> <li> <p>Gentamicin</p> </li> <li> <p>Tobramycin</p> </li> <li> <p>Amikacin</p> </li> <li> <p>Netilmicin</p> </li> <li> <p>Kanamycin</p> </li> </ul> </li> </ul> </p> </section> <section id="CD003038-sec-0037"> <h4 class="title">Types of outcome measures</h4> <section id="CD003038-sec-0038"> <h5 class="title">Primary outcomes</h5> <p>Death at end of follow‐up for the infectious episode, up to 30 days (all cause mortality).</p> </section> <section id="CD003038-sec-0039"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003038-list-0009"> <li> <p>Treatment failure: a composite end point comprising one or more of the following: death; persistence, recurrence or worsening of clinical signs or symptoms of presenting infection; any modification of the assigned empirical antibiotic treatment. </p> </li> <li> <p>Infection related mortality, as reported in the study.</p> </li> <li> <p>Duration of hospital stay.</p> </li> <li> <p>Dropouts before end of study.</p> </li> <li> <p>Super‐infection: new, persistent or worsening symptoms and/or signs of infection associated with the isolation of a new pathogen (different, or different susceptibilities) or the development of a new site of infection. </p> </li> <li> <p>Colonisation: isolation during or after therapy of Gram‐negative bacteria resistant to the beta‐lactam included in the empirical regimen, without symptoms or signs of infection. </p> </li> </ul> </p> <section id="CD003038-sec-0040"> <h6 class="title">Adverse effects</h6> <p> <ul id="CD003038-list-0010"> <li> <p>Life threatening or associated with permanent disability.</p> </li> <li> <p>Serious－requiring discontinuation of therapy.</p> </li> <li> <p>Any other.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD003038-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003038-sec-0042"> <h4 class="title">Electronic searches</h4> <p>Relevant randomised trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>, Issue 7, 2012), LILACS to August 2012, Database of Abstracts of Reviews of Effects (DARE) (Issue 3, 2012) and MEDLINE and EMBASE to August 2012. We conducted a wide search targeting all randomised trials for the treatment of infection in neutropenic patients for this and other systematic reviews conducted by our group. The detailed search strategies for each database are provided in <a href="./appendices#CD003038-sec-0070">Appendix 1</a>, <a href="./appendices#CD003038-sec-0071">Appendix 2</a> and <a href="./appendices#CD003038-sec-0072">Appendix 3</a>. </p> </section> <section id="CD003038-sec-0043"> <h4 class="title">Searching other resources</h4> <p>References of all identified studies as well as major reviews were inspected for more studies. We checked the conference proceedings of the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) 1995 to 2011, the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2001 to 2012) and the American Society of Hematology (ASH) 2003 to 2011. Letters, abstracts and unpublished trials were accepted to reduce the influence of publication bias. Additionally, the first or corresponding author of each included study and pharmaceutical companies were contacted for complementary information or information regarding unpublished trials. </p> </section> </section> <section id="CD003038-sec-0044"> <h3 class="title" id="CD003038-sec-0044">Data collection and analysis</h3> <section id="CD003038-sec-0045"> <h4 class="title">Selection of studies</h4> <p>One review author inspected the abstract of each reference identified by the search and applied inclusion criteria. For possibly relevant articles, the full article was obtained and inspected by two review authors. </p> </section> <section id="CD003038-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from included trials. In cases of disagreement between the two review authors, a third review author extracted the data. In addition the third review author extracted 10% of the studies, selected randomly. Data extractions were discussed, decisions documented and all authors of included studies contacted for clarification. Justification for excluding studies from the review was also documented. Differences in the data extracted were resolved by discussion. All data were collected on an intention‐to‐treat (ITT) basis whenever possible. </p> </section> <section id="CD003038-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Trials fulfilling the review inclusion criteria were assessed for risk of bias by two review authors working independently. For the 2012 update, this was done using the criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003038-bbs2-0108" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We primarily assessed the effect of allocation concealment on results, based on the evidence of a strong association between poor allocation concealment and overestimation of effect (<a href="./references#CD003038-bbs2-0124" title="SchulzKF , ChalmersI , HayesRJ , AltmanD . Empirical evidence of bias. JAMA1995;273(5):408‐12. ">Schulz 1995</a>), as defined below: </p> <p> <ul id="CD003038-list-0011"> <li> <p>Low risk of bias (adequate allocation concealment).</p> </li> <li> <p>Moderate risk of bias (uncertainty regarding allocation concealment).</p> </li> <li> <p>High risk of bias (inadequate allocation concealment).</p> </li> </ul> </p> <p>In addition to the adequacy of allocation concealment, methods of allocation generation, blinding, incomplete outcome data, selective reporting, the unit of randomisation (patient or febrile episode) and publication status were recorded independently by the two review authors. </p> </section> <section id="CD003038-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity in the results of the trials was initially graphically inspected and assessed by calculating a test of heterogeneity (Chi‐square). We anticipated between‐trial variation in estimation of morbidity and mortality for studies comparing the same beta‐lactam and studies comparing different beta‐lactams (<a href="./references#CD003038-bbs2-0102" title="ElphickHE , TanA . Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002007] ">Elphick 2001</a>). These were separated when heterogeneity was observed. Further heterogeneity was explored through subgroup analysis, assessing the above‐defined patient subgroups (<a href="#CD003038-sec-0031">Objectives</a>). </p> <p>A funnel plot estimating the precision of trials (plots of the log of the risk ratio for efficacy against the sample size) was examined to estimate potential selection bias (such as publication bias) and to assess whether effect estimates are associated with study size. </p> <p>Adjusted means were calculated and corrected by the inverse of the variance. We searched for the correlation between mortality and treatment failure, to assess the clinical relevance of treatment failure and infection related mortality outcomes in these studies. Correlations were tested for significance using a non‐parametric test (Spearman) using the Statistical Package for the Social Sciences (SPSS) version 14.0. Numbers needed to treat or harm were calculated as 1/(CER‐CER*RR), where CER is the control event rate and RR is the risk ratio. </p> </section> <section id="CD003038-sec-0049"> <h4 class="title">Data synthesis</h4> <p>Dichotomous data were analysed by calculating the risk ratio (RR) for each trial with the uncertainty in each result expressed with the use of 95% confidence intervals (CIs). A fixed‐effect model was used throughout the review, unless significant heterogeneity was observed (P &lt; 0.1 or I<sup>2</sup> &gt; 50%) where the random‐effects model was used. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003038-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003038-sec-0050"></div> <section id="CD003038-sec-0051"> <h3 class="title">Description of studies</h3> <p>The computerised search strategy identified a large number of randomised trials assessing the treatment of febrile neutropenia－not all of which were relevant for the present review. These were screened for trials assessing beta‐lactam‐aminoglycoside combination therapy versus beta‐lactam monotherapy. Ninety‐five publications of RCTs were considered eligible for this review. </p> <p>Twenty‐three publications of 22 trials were excluded (<a href="./references#CD003038-sec-0082" title="">Characteristics of excluded studies</a>). Allocation to monotherapy versus combination therapy was non‐random in five studies, randomisation to monotherapy versus combination therapy was semi‐empirical in three trials (<a href="./references#CD003038-bbs2-0073" title="BodeyGP , FeldR , BurgessMA . Beta‐lactam antibiotics alone or in combination with gentamicin for therapy of gram‐negative bacillary infections in neutropenic patients. American Journal of Medicine1976;271(2):179‐86. ">Bodey 1976</a>; <a href="./references#CD003038-bbs2-0078" title="The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram‐negative bacteremia in cancer patients with granulocytopenia. New England Journal of Medicine1987;317(27):1692‐8. ">EORTC 1987</a>; <a href="./references#CD003038-bbs2-0086" title="PegramPS , PhairJP , McMahanR , MurphyRL , GordonLI , WashtonH , et al. Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. Journal of Antimicrobial Chemotherapy1989;24(4):591‐604. ">Pegram 1989</a>), the comparator regimens were incompatible with our inclusion criteria in nine trials, and non‐neutropenic patients were included in three trials (<a href="./references#CD003038-bbs2-0076" title="D'AntonioD , FioritoniG , IaconeA , Dell'IsolaM , NataleD , D'ArcangeloL , et al. Randomized comparison of ceftriaxone versus ceftriaxone plus amikacin for the empirical treatment of infections in patients with altered host defense: microbiological and clinical evaluation. Chemotherapy1992;38(6):420‐7. ">D'Antonio 1992</a>; <a href="./references#CD003038-bbs2-0079" title="FainsteinV , BodeyGP , EltingL , BolivarR , KeatingMJ , McCredieKB , et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. Journal of Antimicrobial Chemotherapy1983;12:Suppl A:101‐10. ">Fainstein 1983</a>; <a href="./references#CD003038-bbs2-0082" title="HoepelmanIM , Rozenberg‐ArskaM , VerhoefJ . Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora. Chemotherapy1988;34:Suppl 1:21‐9. HoepelmanIM , Rozenberg‐ArskaM , VerhoefJ . Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet1988;1(8598):1305‐9. ">Hoepelman 1988</a>), in which results for neutropenic patients only could not be extracted. One trial randomly assigned participants to treatment with ticarcillin‐clavulanate versus ticarcillin‐clavulanate+amikacin; however participants who had undergone bone marrow transplantation were allocated to combination therapy only, over‐riding the random allocation (<a href="./references#CD003038-bbs2-0074" title="BruJP , MichalletM , LegrandC , SwierzP , StahlJP , LeautetJB , et al. A prospective randomized study comparing the efficacy of timentin alone or in combination with amikacin in the treatment of febrile neutropenic patients. Journal of Antimicrobial Chemotherapy1986;17:Suppl C:203‐9. ">Bru 1986</a>); another trial comparing imipenem versus ceftazidime versus amikacin was excluded, because it was presented as an ongoing study in a conference in 1986, no further publication of the study was found and we were not able to contact the authors (<a href="./references#CD003038-bbs2-0084" title="Moreno‐SanchezFGR , LazaroRM , TellezE , TorresE . Monotherapy in patients with neutropenic fever. Proceedings of the American Society for Clinical Oncology. 1992:Abstract No. 1364. ">Moreno‐Sanchez 1992</a>). </p> <p>We could not yet obtain the full text of one trial, which is awaiting assessment (<a href="./references#CD003038-bbs2-0094" title="LiHC , ZhangM , YeX . Evidence of treating febrile neutropenia with netilmicin‐ceftazidime. Clinical Assembly1998;13(23):1057‐8. ">Li 1998</a>). Another trial was presented at a conference in 2005 and is listed as ongoing (<a href="./references#CD003038-bbs2-0095" title="BilgirO , KadikoyluV , BilgirF . The comparison of imipenem with piperacillin/tazobactam and amikacin combination in patients with hematological malignancies in the treatment of febrile neutropenia. Proceedings of the 10th Congress of the European Hematology Association. 2005:Abstract No. 1021. ">Bilgir 2005</a>). </p> <p>Seventy‐one trials described in 89 publications are included in the review (<a href="./references#CD003038-sec-0081" title="">Characteristics of included studies;</a> secondary publications are listed under their primary reference). The trials were published between 1983 and 2012. Three trials were added since the previous version of this review, all published between 2007 and 2012. Forty‐three trials reported data on all cause mortality and 41 reported on infection related mortality. Data regarding treatment failure were available for all trials. Thirty‐one trials contained usable information for super‐infections, and 49 trials are included in the adverse event analysis. </p> <p>Eight included trials, presented in conference proceedings between 1987 and 2002, were published in abstract form only. Supplementary data from the authors were available for two of these (<a href="./references#CD003038-bbs2-0014" title="CornelyOA , ReichertD , BuchheidtD , MaschmeyerG , WilhelmM , ChielX (for the Paul‐Erlich‐Gesellschaft) . Three‐armed multicenter randomized study on the empiric treatment of neutropenic fever in a high risk patient population (PEG study III). Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy;Abstract L‐775. 2001. MaschmeyerG . Cefepime in the empirical initial treatment of febrile neutropenic cancer patients [Cefepim in der empirischen Initial therapie bei febrilen neutropenischen Patienten mit mignen erkankungen]. Chemotherapie Journal2004;13:174‐180. ">Cornely 2001</a>, <a href="./references#CD003038-bbs2-0030" title="HenseJ , BertzH , LeifertJ , MeusersP , MertelsmannR , BrittingerG . Final results of a prospective randomized trial of bolus meropenem versus infusion meropenem versus ceftazidime/amikacin as empiric initial therapy for infections and fever of unknown origin in neutropenic patients with hematologic malignancies. Supportive Care in Cancer2000;8:Suppl:160. Abstract 64. HenseJ , UppenkampM , MeusersP , HofelerH , BrittingerG . Prospective randomized trial of bolus meropenem versus infusion meropenem versus ceftazidime/amikacin as empiric initial therapy for infections and fever of unknown origin in neutropenic patients with hematologic malignancies. Annals of Hematology1998;77:Suppl 2:S199. ">Hense 2000</a>). Additional information on trial methods and/or on mortality was available from 24 full‐text publications ('unpublished data' in the reference description). </p> <section id="CD003038-sec-0052"> <h4 class="title">Patient and infection characteristics</h4> <p>Most trials included adult cancer patients. Fourteen trials included only children, and another 14 trials included both adults and children. Most trials included participants with haematological cancer: 35 trials included only patients with haematological malignancies, and in another 32 trials most patients had haematological cancer. Bone marrow transplant patients were excluded from three trials. Patients with septic shock were specifically excluded from four trials; most trials did not refer to patients with septic shock, and in the few trials that did report patients with septic shock, only a few patients were included (1% to 6% of patients in five trials reporting the number of patients with shock on admission). </p> <p>The ratio between Gram‐negative and Gram‐positive bacteria among all included studies was 0.69. The adjusted mean rate of infection caused by Gram‐negative bacteria was 11.5% of participants. <i>Pseudomonas aeruginosa</i>, a commonly implicated pathogen of febrile neutropenia in the past, was isolated in only 1.7% of included participants, constituting 15.3% of all documented Gram‐negative isolates. </p> <p>Surveillance cultures were performed in nine trials.</p> </section> <section id="CD003038-sec-0053"> <h4 class="title">Antibiotic regimens</h4> <p>The same beta‐lactam was compared in 16 of 71 included trials. In these trials the beta‐lactam was ceftazidime (seven trials), piperacillin‐tazobactam (four trials), cefepime (three trials), imipenem (two trials－one of which included four arms and assessed both ceftazidime and imipenem) and cefoperazone (one trial). All other trials compared one beta‐lactam (usually a new drug) with a narrower‐spectrum beta‐lactam combined with an aminoglycoside. The most common mono‐combi beta‐lactam comparison was between a carbapenem and a cephalosporin (18 trials). Other comparisons included cephalosporin‐cephalosporin (11 trials), cephalosporin‐penicillin (nine trials), carbapenem‐penicillin (nine trials), penicillin‐cephalosporin (four trials) and penicillin‐penicillin (three trials), respectively. </p> <p>The most commonly tested aminoglycoside was amikacin (43 trials), followed by tobramycin (14 trials), gentamicin (11 trials) and netilmicin (three trials). Aminoglycosides were administered once daily in 16 trials. Aminoglycosides were administered for the duration of treatment in all trials, except <a href="./references#CD003038-bbs2-0066" title="TamuraK , ImajoK , AkiyamaN , SuzukiK , UrabeA , OhyashikiK , et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clinical Infectious Diseases2004;39:S15‐24. ">Tamura 2004</a>, where amikacin was administered only for the first 3 days of combination therapy. </p> <p>Treatment duration was reported as means or medians. The mean treatment duration ranged from 7 to 15 days (most commonly 9 days); median treatment duration varied between 4 and 9 days (most commonly 9 days). </p> </section> </section> <section id="CD003038-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>Adequate allocation concealment, using sealed opaque envelopes or central randomisation, was described in 27 trials (<a href="./references#CD003038-bbs2-0002" title="AhmedN , BorollosyN , BeshlawyA , MahallawyH , HaddadA . Outpatient single dose ceftriaxone and amikacin vs. imipenem/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever and neutropenia: a randomized, prospective clinical trial. Proceedings of Meeting of the American Society of Hematology; Abstract No. 887. 2003. AhmedN , BorollosyN , BeshlawyA , MahallawyH , HaddadA . Outpatient single dose ceftriaxone and amikacin vs. imipenem/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever aneutropenia: a randomized, prospective clinical trial. Proceedings of ASCO Meeting; Abstract No. 8520. 2004. AhmedN , MahallawyHA , AhmedIA , NassifS , BeshlawyA , HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood Cancer2007;49:786‐92. ">Ahmed 2007</a>; <a href="./references#CD003038-bbs2-0003" title="AkovaM , AkanH , KortenV , BiberogluK , HayranM , UnalS , et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. International Journal of Antimicrobial Agents1999;13(1):15‐9. ">Akova 1999</a>; <a href="./references#CD003038-bbs2-0004" title="AlanisA , RehmS , WeinsteinAJ . Comparative efficacy and toxicity of moxalactam and the combination of nafcillin and tobramycin in febrile granulocytopenic patients. Cleveland Clinic Quarterly1983;50(4):385‐95. ">Alanis 1983</a>; <a href="./references#CD003038-bbs2-0007" title="BehreG , LinkH , MaschmeyerG , MeyerP , PaazU , WilhelmM , et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Annals of Hematology1998;76(2):73‐80. ">Behre 1998</a>; <a href="./references#CD003038-bbs2-0010" title="ComettaA , CalandraT , GayaH , ZinnerSH , DeBockR , DelFaveroA , et al(EORTC) . Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy1996;40(5):1108‐15. ">Cometta 1996</a>; <a href="./references#CD003038-bbs2-0014" title="CornelyOA , ReichertD , BuchheidtD , MaschmeyerG , WilhelmM , ChielX (for the Paul‐Erlich‐Gesellschaft) . Three‐armed multicenter randomized study on the empiric treatment of neutropenic fever in a high risk patient population (PEG study III). Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy;Abstract L‐775. 2001. MaschmeyerG . Cefepime in the empirical initial treatment of febrile neutropenic cancer patients [Cefepim in der empirischen Initial therapie bei febrilen neutropenischen Patienten mit mignen erkankungen]. Chemotherapie Journal2004;13:174‐180. ">Cornely 2001</a>; <a href="./references#CD003038-bbs2-0015" title="De laCamaraR , FigueraA , SuredaA , HermidaG , VergeG , OlallaI , et al. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. Haematologica1997;82(6):668‐75. ">De la Camara 1997</a>; <a href="./references#CD003038-bbs2-0016" title="DelFaveroA , MenichettiF , MartinoP , BucaneveG , MicozziA , GentileG , et al. A multicenter, double‐blind, placebo‐controlled trial comparing piperacillin‐tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clinical Infectious Diseases2001;33(8):1295‐301. DelFaveroA , MicozziA , BucaneveG , MartinoP . Double‐blind, randomised, clinical trial comparing monotherapy with piperacillin‐tazobactam vs piperacillin‐tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract No. 1092. 1999. MicozziA , BucaneveG , MenichettiF , MartinoP , DelFaveroA , G.I.M.E.M.A.Infection Program. Double blind, randomized, clinical trial comparing monotherapy with piperacillin‐tazobactam versus piperacillin‐tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients.. Supportive Care in Cancer2000;8 Suppl:160, Abstract 63. ">Del Favero 2001</a>; <a href="./references#CD003038-bbs2-0018" title="DePauwBE , DeresinskiSC , FeldR , Lane AllmanEF , DonnellyJP . Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Annals of Internal Medicine1994;120(10):834‐44. DePauwBE , FeldR , DeresinskiS , DonnellyJP , Lane‐AllmanE . Multicentre, randomised, comparative study of ceftazidime vs piperacillin as empirical therapy for febrile granulocytic patients. Proceedings of the Sixth International Symposium of Infections in the Immunocompromised Host. Abstract No 116. 1990. DompelingEC , DonnellyJP , DeresinskiSC , FeldR , Lane AllmanEF , DePauwBE . Early identification of neutropenic patients at risk of gram positive bacteraemia and the impact of empirical administration of vancomycin. European Journal of Cancer1996;32a(8):1332‐9. ">De Pauw 1994</a>; <a href="./references#CD003038-bbs2-0026" title="GibsonJ , DateL , JoshuaDE , YoungGA , WilsonA , BennR , et al. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin. Australian and New Zealand Journal of Medicine1989;19(5):417‐25. ">Gibson 1989</a>; <a href="./references#CD003038-bbs2-0027" title="GlasmacherA , HahnC , MolitorE , FixsonA , MeyU , SauerbruchT , et al. A randomized comparison of piperacillin‐tazobactam vs. ceftriaxone and gentamicin in 172 severely neutropenic patients with hematologic malignancies. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999:Abstract 1090. GorschluterM , HahnC , FixsonA , MeyU , ZiskeC , MolitorE , et al. Piperacillin‐tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Supportive Care in Cancer2003;11(6):362‐70. ">Gorschluter 2003</a>; <a href="./references#CD003038-bbs2-0031" title="HessUBC , ReyK , SennHJ . Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Supportive Care in Cancer1998;6:402‐9. ">Hess 1998</a>; <a href="./references#CD003038-bbs2-0034" title="JimenoA , ArcedianoA , BazaresS , AmadorML , Gonzalez‐CortijoL , CiruelosE , et al. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia. Clinical Transplantation and Oncology2006;8(12):889‐95. JimenoA , ArcedianoA , GomezC , BezaresS , CastellanoD , Paz‐AresL , et al. Randomized study of cefepime versus ceftazidime plus amikacin in febrile neutropenic patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS). Proceedings of the Annual Meeting of the American Society of Clinical Oncology; Abstract 3387. 2003. ">Jimeno 2006</a>; <a href="./references#CD003038-bbs2-0036" title="KinseySE , MachinSJ , GoldstoneAH . Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. Journal of Hospital Infection1990;15:49‐53. ">Kinsey 1990</a>; <a href="./references#CD003038-bbs2-0040" title="LeylandMJ , BaystK , CohenJ , WarrenR , NewlandAC , BintAJ , et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. Journal of Antimicrobial Chemotherapy1992;30(6):843‐54. ">Leyland 1992</a>; <a href="./references#CD003038-bbs2-0041" title="LieschkeGJ , BellD , RawlinsonW , GreenM , SheridanW , MorstynG , et al. Imipenem/cilastatin versus tobramycin and piperacillin as initial empiric therapy for febrile episodes in neutropenic patients: interim analysis of a prospective randomized comparison. Australian and New Zealand Journal of Medicine1990;3:Suppl 1:424. ">Lieschke 1990</a>; <a href="./references#CD003038-bbs2-0043" title="MarieJP , PicoJ , LapierreV , MaulardC , PappoM , ChicheD , et al. Comparative trial of ceftazidime alone, ceftazidime + amikacin and ceftazidime + vancomycin as empiric therapy of febrile cancer patients with induced prolonged neutropenia [Traitement empirique des episodes febriles survenant chez les patients cancereux presentant une neutropenie prolongee: essai comparatif ceftazidime seule, ceftazidime+amikacine et ceftazidime+vancomycine]. Medicine et Maladies Infectieuses1991;21:386‐8. MarieJP , PicoJL , ChicheD , FitoussiF , DelmerA , BaumeD , et al. [Antibiotic therapy protocol using ceftazidime 3g/day alone or in combination with vancomycin or amikacin. In febrile episodes in neutropenic patients]. [French] [Protocole d'antibiotherie utilisant la ceftazidime a la dose de 3g/jour seule ou en association avec la vancomycin ou l'amikacin]. Presse Medicale1988;17(37):1968‐70. MarieJP , VekhoffA , PicoJL , GuyH , AndremontA , RichetH . Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. Journal of Antimicrobial Chemotherapy1998;41(Suppl D):57‐64. PicoJL , MarieJP , ChicheD , GuiguetM , AndremontA , LapierreV , et al. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. Eur J Med1993;2(5):275‐80. ">Marie 1991</a>; <a href="./references#CD003038-bbs2-0044" title="MatsuiK , MasudaN , TakadaM , KusunokiY , FukuokaM . A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Jpn J Clin Oncol1991;21(6):428‐34. ">Matsui 1991</a>; <a href="./references#CD003038-bbs2-0047" title="NorrbySR , VandercamB , LouieT , RundeV , NorbergB , AnnikoM , et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multiclinic study. Scandinavian Journal of Infectious Diseases Supplement1987;52:65‐78. VandercamB , EzzeddineH , AgaliotisD , GalaJL , GigiJ , WautersG , et al. Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies. Acta Clinica Belgica1989;44(2):99‐109. ">Norrby 1987</a>; <a href="./references#CD003038-bbs2-0049" title="NovakovaIR , DonnellyJP , dePauwBE . Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. Annals of Hematology1991;63(4):195‐200. ">Novakova 1991</a>; <a href="./references#CD003038-bbs2-0048" title="NovakovaI , DonnellyP , DePauwB . Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. Scandinavian Journal of Infectious Diseases1990;22(6):705‐11. ">Novakova 1990</a>; <a href="./references#CD003038-bbs2-0087" title="PetrilliAS , MelarangoR , BianchiA , KussanoE , BarrosKVT , SilvaAAM . Fever and neutropenia in children: a new therapeutic proposal. Revista da Associação Médica Brasileira1991;37(4):173‐80. ">Petrilli 1991</a>; <a href="./references#CD003038-bbs2-0058" title="PickardW , DurackD , GallisH . A randomized trial of empiric therapy with moxalactam versus tobramycin plus ticarcillin in febrile, neutropenic patients. Current Choices in Antibiotic Therapy for Febrile Episodes in Neutropenic Patients. 1983. PickardW , DurackD , GallisH . A randomized trial of moxalactam versus tobramycin plus ticarcillin in 50 febrile neutropenic patients. Proceedings of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract No. 66. 1982. PickardW , GallisHA , DurackDT . A randomized trial of empiric therapy with moxalactam versus tobramycin plus ticarcillin in febrile neutropenic patients. Proceedings of the Second International Symposium in Infections in the Immunocompromised Host. 1982. ">Pickard 1983</a>; <a href="./references#CD003038-bbs2-0065" title="TamuraK , MatsuokaH , TsukadaJ , MasudaM , IkedaS , MatsuishiE , et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th‐generation cephalosporin + aminoglycosides: comparative study. Am J Hematol2002;71:248‐55. ">Tamura 2002</a>; <a href="./references#CD003038-bbs2-0066" title="TamuraK , ImajoK , AkiyamaN , SuzukiK , UrabeA , OhyashikiK , et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clinical Infectious Diseases2004;39:S15‐24. ">Tamura 2004</a>; <a href="./references#CD003038-bbs2-0068" title="Wrzesien‐KusA , JamroziakK , WierzbowskaA , RobakT . Cefepime in monotherapy or in combination with amikacine as the empirical treatment of febrile neutropenic patients. Acta Haematologica Polonica2001;32(2):165‐72. ">Wrzesien‐Kus 2001</a>; <a href="./references#CD003038-bbs2-0069" title="RamphalR , GucalpR , RotsteinC , CiminoM , OblonD . Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. American Journal of Medicine1996;100(6a):83s‐9s. YamamuraD , GucalpR , CarlisleP , CiminoM , RobertsJ , RotsteinC . Open randomized study of cefepime versus piperacillin‐gentamicin for treatment of febrile neutropenic cancer patients. Antimicrobial Agents and Chemotherapy1997;41(8):1704‐8. ">Yamamura 1997</a>). Allocation generation was adequate in a similar number of studies. These studies used tables of random numbers or computer‐generated lists. Allocation concealment was inadequate in two trials describing the randomisation only as consecutive (<a href="./references#CD003038-bbs2-0012" title="CorapciogluF , SarperN . Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatric Hematologic Oncology2005;22(1):59‐70. ">Corapcioglu 2005</a>; <a href="./references#CD003038-bbs2-0071" title="ZenginE , SarperN , KiliçS . Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatric Hematology and Oncology2011;28:311‐20. ">Zengin 2011</a>). Randomisation methods were not described in all other trials. Four trials were double‐blinded (<a href="./references#CD003038-bbs2-0016" title="DelFaveroA , MenichettiF , MartinoP , BucaneveG , MicozziA , GentileG , et al. A multicenter, double‐blind, placebo‐controlled trial comparing piperacillin‐tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clinical Infectious Diseases2001;33(8):1295‐301. DelFaveroA , MicozziA , BucaneveG , MartinoP . Double‐blind, randomised, clinical trial comparing monotherapy with piperacillin‐tazobactam vs piperacillin‐tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract No. 1092. 1999. MicozziA , BucaneveG , MenichettiF , MartinoP , DelFaveroA , G.I.M.E.M.A.Infection Program. Double blind, randomized, clinical trial comparing monotherapy with piperacillin‐tazobactam versus piperacillin‐tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients.. Supportive Care in Cancer2000;8 Suppl:160, Abstract 63. ">Del Favero 2001</a>; <a href="./references#CD003038-bbs2-0050" title="OzyilkanO , YalcintasU , BaskanS . Imipenem‐cilastatin versus sulbactam‐cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. The Korean Journal of Internal Medicine1999;14(2):15‐9. ">Ozyilkan 1999</a>; <a href="./references#CD003038-bbs2-0063" title="SchuchterL , KaelinW , PettyB , WingardJ , AltomonteV , DickJ , et al. Ceftazidime vs ticalcillin and gentamicin in febrile neutropenic bone marrow transplant patients: a prospective, randomized, double‐blind trial. Blood1988;Abstract 1534(Suppl 1):1:406a. ">Schuchter 1988</a>; <a href="./references#CD003038-bbs2-0128" title="WadeJC . Antibiotic therapy for the febrile granulopenic cancer patient: combination therapy versus monotherapy. Review of Infectious Diseases1989;11:Suppl 7:S1572‐81. ">Wade 1989</a>), four single‐blinded (<a href="./references#CD003038-bbs2-0010" title="ComettaA , CalandraT , GayaH , ZinnerSH , DeBockR , DelFaveroA , et al(EORTC) . Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy1996;40(5):1108‐15. ">Cometta 1996</a>; <a href="./references#CD003038-bbs2-0021" title="DuzovaA , KutlukT , KanraG , BuyukpamukcuM , AkyuzC , SecmeerG , Ceyhan , M . Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. The Turkish Journal of Pediatrics2001;43(2):105‐9. ">Duzova 2001</a>; <a href="./references#CD003038-bbs2-0040" title="LeylandMJ , BaystK , CohenJ , WarrenR , NewlandAC , BintAJ , et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. Journal of Antimicrobial Chemotherapy1992;30(6):843‐54. ">Leyland 1992</a>; <a href="./references#CD003038-bbs2-0062" title="RolstonKV , BerkeyP , BodeyGP , AnaissieEJ , KhardoriNM , JoshiJH , et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Archives of Internal Medicine1992;152(2):283‐91. ">Rolston 1992</a>) and the remainder open‐randomised trials. </p> <p>Intention‐to‐treat (ITT) analysis was presented in 23 of 68 trials included for treatment failure analysis and in 25 of 47 trials included for mortality analysis. Dropouts were reported by their allocation group in 26 of the 45 trials presenting per protocol analysis for treatment failure, permitting a secondary ITT analysis in which dropouts were assumed to be failures (see later, sensitivity analyses for failure). The number of patients excluded from analysis in studies in which ITT analysis was impossible ranged between 3% and 30% and the median rate of excluded patients was 10%. Twelve trials, mostly presented as conference proceedings, addressed 'treated' or 'evaluated' patients, without specifying a different figure for the number of randomly assigned participants (<a href="./references#CD003038-bbs2-0001" title="AgaogluL , DeveciogluO , AnakS , KarakasZ , YalmanN , BinerB , et al. Cost‐effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. Journal of Chemotherapy2001;13(3):281‐7. ">Agaoglu 2001</a>; <a href="./references#CD003038-bbs2-0009" title="BorbollaJR , Lopez‐HernandezMA , Gonzalez‐AvanteM , DeDiegoJ , TruebaE , AlvaradoML , et al. Comparison of cefepime versus ceftriaxone‐amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients. Chemotherapy2001;47(5):381‐4. ">Borbolla 2001</a>; <a href="./references#CD003038-bbs2-0021" title="DuzovaA , KutlukT , KanraG , BuyukpamukcuM , AkyuzC , SecmeerG , Ceyhan , M . Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. The Turkish Journal of Pediatrics2001;43(2):105‐9. ">Duzova 2001</a>; <a href="./references#CD003038-bbs2-0022" title="ElHaddadAMA . Comparison of cefoperazone‐sulbactam versus piperacillin plus amikacin as empiric therapy in pediatric febrile neutropenic cancer patients. Current Therapeutic Research Clinical and Experimental1995;56(10):1094‐9. ">El Haddad 1995</a>; <a href="./references#CD003038-bbs2-0024" title="EsteveJ , NomdedeuB , MensaJ , GuardiaR , MarcoF , MontserratE . Piperacillin/tazobactam vs. piperacillin/tazobactam plus amikacin as empiric therapy for fever in neutropenic patients. Blood1997;10(Suppl 1 (Pt 2)):229b. Abstract 3767. ">Esteve 1997</a>; <a href="./references#CD003038-bbs2-0025" title="Gaytan‐MartinezJE , Mateos‐GarciaE , CasanovaLJ , Fuentes‐AllenJL , Sanchez‐CortesE , Manjarrez‐TellezB , et al. Efficacy of empirical therapy with cefepime compared with ceftazidime plus amikacin in febrile neutropenic patients. Proceedings of the Annual Meeting of the American Society of Hematology. 2002:Abstract No. 3655. ">Gaytan‐Martinez 2002</a>; <a href="./references#CD003038-bbs2-0037" title="KliasovaG , SavchenkoV , LubimovaL , MendeleevaL , ParovichnikovaE , TolkachevaT , et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for febrile neutropenic bone marrow transplant patients. Proceedings of the 11th European Congress of Clinical Microbiology and Infectious Diseases. 2001. [MEDLINE: http://www.akm.ch/eccmid2001/] ">Kliasova 2001</a>; <a href="./references#CD003038-bbs2-0043" title="MarieJP , PicoJ , LapierreV , MaulardC , PappoM , ChicheD , et al. Comparative trial of ceftazidime alone, ceftazidime + amikacin and ceftazidime + vancomycin as empiric therapy of febrile cancer patients with induced prolonged neutropenia [Traitement empirique des episodes febriles survenant chez les patients cancereux presentant une neutropenie prolongee: essai comparatif ceftazidime seule, ceftazidime+amikacine et ceftazidime+vancomycine]. Medicine et Maladies Infectieuses1991;21:386‐8. MarieJP , PicoJL , ChicheD , FitoussiF , DelmerA , BaumeD , et al. [Antibiotic therapy protocol using ceftazidime 3g/day alone or in combination with vancomycin or amikacin. In febrile episodes in neutropenic patients]. [French] [Protocole d'antibiotherie utilisant la ceftazidime a la dose de 3g/jour seule ou en association avec la vancomycin ou l'amikacin]. Presse Medicale1988;17(37):1968‐70. MarieJP , VekhoffA , PicoJL , GuyH , AndremontA , RichetH . Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. Journal of Antimicrobial Chemotherapy1998;41(Suppl D):57‐64. PicoJL , MarieJP , ChicheD , GuiguetM , AndremontA , LapierreV , et al. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. Eur J Med1993;2(5):275‐80. ">Marie 1991</a>; <a href="./references#CD003038-bbs2-0052" title="PegramSP , MussHB , McGallCE , CooperRM , WhiteDR , RichardsF , et al. A comparative study of moxalactam vs. ticarcillin and tobramycin in febrile, neutropenic cancer patients. Proceedings of the Annual Meetings of the American Society of Clinical Oncology; Abstract No. 255. 1982. PegramSP , MussHB , McGallCE , CooperRM , WhiteDR , RichardsT , et al. A comparative study of moxalactam vs. ticarcillin and tobramycin in febrile, neutropenic cancer patients. Proceedings of the Annual Meetings of the American Society of Clinical Oncology; Abstract No. 391. 1984. ">Pegram 1984</a>; <a href="./references#CD003038-bbs2-0053" title="PellegrinJL , MaritG , FourcheJ , BroustetA , TexierMJ , LengB , et al. Response to infection in patients with acute leukemia during remission induction treatment: ceftazidime versus cefotaxime + tobramycin [Etude prospective randomisee de la ceftazidime versus l'association cefotaxime‐tobramycine, dans les leucemies aigues en aplasie therapeutique]. Presse Med1988;17(37):1960‐3. ">Pellegrin 1988</a>; <a href="./references#CD003038-bbs2-0063" title="SchuchterL , KaelinW , PettyB , WingardJ , AltomonteV , DickJ , et al. Ceftazidime vs ticalcillin and gentamicin in febrile neutropenic bone marrow transplant patients: a prospective, randomized, double‐blind trial. Blood1988;Abstract 1534(Suppl 1):1:406a. ">Schuchter 1988</a>; <a href="./references#CD003038-bbs2-0067" title="BustamanteCI . Initial empiric therapy for fever in neutropenia. Recent Results in Cancer Research1993;132:45‐56. WadeJC . Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy versus monotherapy. Reviews of Infectious Diseases1989;11:Suppl 7:S1572‐81. WadeJC , DelinA , FinelyR , DrusanoG , ThompsonB . Imipenem versus piperacillin plus amikacin, empiric therapy for febrile neutropenic patients: a double blind trial. Proceedings of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1987:Abstract No. 1251. ">Wade 1987</a>). The analysis presumed for these studies was per‐protocol. </p> <p>A pre‐determined, defined follow‐up period was available from the publication or through author contact for 14 included trials (<a href="./references#CD003038-bbs2-0007" title="BehreG , LinkH , MaschmeyerG , MeyerP , PaazU , WilhelmM , et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Annals of Hematology1998;76(2):73‐80. ">Behre 1998</a>; <a href="./references#CD003038-bbs2-0010" title="ComettaA , CalandraT , GayaH , ZinnerSH , DeBockR , DelFaveroA , et al(EORTC) . Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy1996;40(5):1108‐15. ">Cometta 1996</a>; <a href="./references#CD003038-bbs2-0015" title="De laCamaraR , FigueraA , SuredaA , HermidaG , VergeG , OlallaI , et al. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. Haematologica1997;82(6):668‐75. ">De la Camara 1997</a>; <a href="./references#CD003038-bbs2-0016" title="DelFaveroA , MenichettiF , MartinoP , BucaneveG , MicozziA , GentileG , et al. A multicenter, double‐blind, placebo‐controlled trial comparing piperacillin‐tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clinical Infectious Diseases2001;33(8):1295‐301. DelFaveroA , MicozziA , BucaneveG , MartinoP . Double‐blind, randomised, clinical trial comparing monotherapy with piperacillin‐tazobactam vs piperacillin‐tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract No. 1092. 1999. MicozziA , BucaneveG , MenichettiF , MartinoP , DelFaveroA , G.I.M.E.M.A.Infection Program. Double blind, randomized, clinical trial comparing monotherapy with piperacillin‐tazobactam versus piperacillin‐tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients.. Supportive Care in Cancer2000;8 Suppl:160, Abstract 63. ">Del Favero 2001</a>; <a href="./references#CD003038-bbs2-0027" title="GlasmacherA , HahnC , MolitorE , FixsonA , MeyU , SauerbruchT , et al. A randomized comparison of piperacillin‐tazobactam vs. ceftriaxone and gentamicin in 172 severely neutropenic patients with hematologic malignancies. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999:Abstract 1090. GorschluterM , HahnC , FixsonA , MeyU , ZiskeC , MolitorE , et al. Piperacillin‐tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Supportive Care in Cancer2003;11(6):362‐70. ">Gorschluter 2003</a>; <a href="./references#CD003038-bbs2-0031" title="HessUBC , ReyK , SennHJ . Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Supportive Care in Cancer1998;6:402‐9. ">Hess 1998</a>; <a href="./references#CD003038-bbs2-0039" title="KojimaA , ShinkaiT , SoejimaY , OkamotoH , EguchiK , SasakiY , et al. A randomized prospective study of imipenem‐cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. American Journal of Clinicial Oncology1994;17(5):400‐4. ">Kojima 1994</a>; <a href="./references#CD003038-bbs2-0040" title="LeylandMJ , BaystK , CohenJ , WarrenR , NewlandAC , BintAJ , et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. Journal of Antimicrobial Chemotherapy1992;30(6):843‐54. ">Leyland 1992</a>; <a href="./references#CD003038-bbs2-0047" title="NorrbySR , VandercamB , LouieT , RundeV , NorbergB , AnnikoM , et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multiclinic study. Scandinavian Journal of Infectious Diseases Supplement1987;52:65‐78. VandercamB , EzzeddineH , AgaliotisD , GalaJL , GigiJ , WautersG , et al. Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies. Acta Clinica Belgica1989;44(2):99‐109. ">Norrby 1987</a>; <a href="./references#CD003038-bbs2-0050" title="OzyilkanO , YalcintasU , BaskanS . Imipenem‐cilastatin versus sulbactam‐cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. The Korean Journal of Internal Medicine1999;14(2):15‐9. ">Ozyilkan 1999</a>; <a href="./references#CD003038-bbs2-0064" title="SmithL , WillAM , WilliamsRF , StevensRF . Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children. The Journal of Infection1990;20(3):201‐6. ">Smith 1990</a>; <a href="./references#CD003038-bbs2-0065" title="TamuraK , MatsuokaH , TsukadaJ , MasudaM , IkedaS , MatsuishiE , et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th‐generation cephalosporin + aminoglycosides: comparative study. Am J Hematol2002;71:248‐55. ">Tamura 2002</a>; <a href="./references#CD003038-bbs2-0066" title="TamuraK , ImajoK , AkiyamaN , SuzukiK , UrabeA , OhyashikiK , et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clinical Infectious Diseases2004;39:S15‐24. ">Tamura 2004</a>; <a href="./references#CD003038-bbs2-0069" title="RamphalR , GucalpR , RotsteinC , CiminoM , OblonD . Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. American Journal of Medicine1996;100(6a):83s‐9s. YamamuraD , GucalpR , CarlisleP , CiminoM , RobertsJ , RotsteinC . Open randomized study of cefepime versus piperacillin‐gentamicin for treatment of febrile neutropenic cancer patients. Antimicrobial Agents and Chemotherapy1997;41(8):1704‐8. ">Yamamura 1997</a>). Follow‐up ranged from 72 hours to 1 month following the end of treatment. The observation time was longer than 1 month in two trials (<a href="./references#CD003038-bbs2-0015" title="De laCamaraR , FigueraA , SuredaA , HermidaG , VergeG , OlallaI , et al. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. Haematologica1997;82(6):668‐75. ">De la Camara 1997</a>; <a href="./references#CD003038-bbs2-0050" title="OzyilkanO , YalcintasU , BaskanS . Imipenem‐cilastatin versus sulbactam‐cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. The Korean Journal of Internal Medicine1999;14(2):15‐9. ">Ozyilkan 1999</a>), both of which reported the outcomes at 1 month post‐therapy. In five trials the time of outcome assessment was described more generally as end of treatment, fever, episode or neutropenia (<a href="./references#CD003038-bbs2-0018" title="DePauwBE , DeresinskiSC , FeldR , Lane AllmanEF , DonnellyJP . Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Annals of Internal Medicine1994;120(10):834‐44. DePauwBE , FeldR , DeresinskiS , DonnellyJP , Lane‐AllmanE . Multicentre, randomised, comparative study of ceftazidime vs piperacillin as empirical therapy for febrile granulocytic patients. Proceedings of the Sixth International Symposium of Infections in the Immunocompromised Host. Abstract No 116. 1990. DompelingEC , DonnellyJP , DeresinskiSC , FeldR , Lane AllmanEF , DePauwBE . Early identification of neutropenic patients at risk of gram positive bacteraemia and the impact of empirical administration of vancomycin. European Journal of Cancer1996;32a(8):1332‐9. ">De Pauw 1994</a>; <a href="./references#CD003038-bbs2-0023" title="ErjavecZ , deVries HospersHG , vanKampH , van derWaaijD , HalieMR , DaenenSM . Comparison of imipenem versus cefuroxime plus tobramycin as empirical therapy for febrile granulocytopenic patients and efficacy of vancomycin and aztreonam in case of failure. Scandinavian Journal of Infectious Diseases1994;26(5):585‐95. ">Erjavec 1994</a>; <a href="./references#CD003038-bbs2-0041" title="LieschkeGJ , BellD , RawlinsonW , GreenM , SheridanW , MorstynG , et al. Imipenem/cilastatin versus tobramycin and piperacillin as initial empiric therapy for febrile episodes in neutropenic patients: interim analysis of a prospective randomized comparison. Australian and New Zealand Journal of Medicine1990;3:Suppl 1:424. ">Lieschke 1990</a>; <a href="./references#CD003038-bbs2-0044" title="MatsuiK , MasudaN , TakadaM , KusunokiY , FukuokaM . A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Jpn J Clin Oncol1991;21(6):428‐34. ">Matsui 1991</a>; <a href="./references#CD003038-bbs2-0059" title="PiguetH , PappoM . First‐line treatment of febrile episodes in leukemia in adults: randomized, multicenter study of ceftazidime in single antibiotic therapy versus a cefotaxime‐amikacin combination [Traitment de premiere intention des episodes febriles des leucemies de l'adulte. Etude randomisee, multicentrique de la ceftazidime en monoantibiotherapie versus l'association cefotaxime‐amikacine]. Presse Med1988;17(37):1954‐9. ">Piguet 1988</a>). Two additional trials reported the average follow‐up period of their trials (8 and 14 days) but a fixed time for outcome assessment was not specified (<a href="./references#CD003038-bbs2-0003" title="AkovaM , AkanH , KortenV , BiberogluK , HayranM , UnalS , et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. International Journal of Antimicrobial Agents1999;13(1):15‐9. ">Akova 1999</a>; <a href="./references#CD003038-bbs2-0062" title="RolstonKV , BerkeyP , BodeyGP , AnaissieEJ , KhardoriNM , JoshiJH , et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Archives of Internal Medicine1992;152(2):283‐91. ">Rolston 1992</a>). </p> <p>The unit of randomisation was the patient in 23 of the 71 trials (<a href="./references#CD003038-sec-0081" title="">Characteristics of included studies</a>). Episodes comprised the unit of randomisation in all the other trials, which allowed patient re‐entry for recurrent episodes of fever and neutropenia. The number of participating patients was given in 74% of trials analysing episodes, and the mean episode‐to‐patient ratio in these trials was 1.3 (range 1.02 to 2.07). Trials that allowed repeat randomisation of participants for separate episodes of febrile neutropenia did not adjust their analyses to the 'cluster' effect of episodes within single participants and did not provide an intra‐patient correlation estimate to allow for adjusted analyses in the meta‐analysis. All trials were included in the main analysis and the effect of episode randomisation was assessed through sensitivity analyses. </p> </section> <section id="CD003038-sec-0055"> <h3 class="title" id="CD003038-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD003038-tbl-0001"><b>Summary of findings for the main comparison</b> beta‐lactam monotherapy compared to beta‐lactam‐aminoglycoside combination therapy for Febrile neutropenic cancer patients</a> </p> <section id="CD003038-sec-0056"> <h4 class="title">Overall effectiveness</h4> <p><b><i>All cause mortality</i> </b> :<br/> All cause mortality was reported in 44 trials, including 7186 episodes. A difference in favour of monotherapy was observed overall (RR 0.87, 95% CI 0.75 to 1.02) (<a href="./references#CD003038-fig-0004" title="">Analysis 1.1</a>). This difference was not statistically significant, but there was no heterogeneity (P = 0.95, I<sup>2</sup> = 0) among trials for this combined effect estimate. Similar results were obtained using the random‐effects model (RR 0.88, 95% CI 0.75 to 1.04). Among trials comparing the same beta‐lactam, the RR was 0.74 (95% CI 0.53 to 1.06, 11 trials, 1718 episodes). Among trials comparing different beta‐lactams, the RR was 0.91 (95% CI 0.77 to 1.09, 33 trials, 5468 episodes). Results were similar for trials comparing same and different beta‐lactams with regard to all cause mortality; therefore these trials were combined in all subsequent subgroup and sensitivity analyses for mortality. </p> <p>No significant differences between monotherapy and combination therapy were observed for the planned subgroups. The trend observed was similar for all comparisons, with RRs favouring monotherapy, with no statistical significance. Moreover, effect estimates favouring monotherapy were larger in subgroups designating participants with a potential worst prognosis: </p> <p> <ul id="CD003038-list-0012"> <li> <p>Participants with microbiologically documented infection: 13 trials, 1188 episodes, RR 0.81 (95% CI 0.56 to 1.17) (<a href="./references#CD003038-fig-0013" title="">Analysis 4.1</a>). </p> </li> <li> <p>Participants with bacteraemia: 14 trials, 676 episodes, RR 0.74 (95% CI 0.46 to 1.18) (<a href="./references#CD003038-fig-0015" title="">Analysis 5.1</a>). </p> </li> <li> <p>Participants with microbiologically documented Gram‐negative infection: 16 trials, 376 episodes, RR 0.64 (95% CI 0.37 to1.11) (<a href="./references#CD003038-fig-0017" title="">Analysis 6.1</a>). </p> </li> <li> <p>Participants with documented <i>Pseudomonas aeruginosa</i> infection: 9 trials, 71 episodes, RR 0.87 (95% CI 0.34 to 2.24) (<a href="./references#CD003038-fig-0019" title="">Analysis 7.1</a>). </p> </li> <li> <p>Participants with haematological cancer: 22 trials 3463 episodes, RR 0.88 (95% CI 0.68 to 1.13) (<a href="./references#CD003038-fig-0021" title="">Analysis 8.1</a>). </p> </li> <li> <p>Participants with severe neutropenia on admission: 6 trials, 737 episodes, RR 0.68 (95% CI 0.37 to 1.24) (<a href="./references#CD003038-fig-0023" title="">Analysis 9.1</a>). </p> </li> </ul> </p> <p>When the analysis was separated by the monotherapy beta‐lactam (<a href="./references#CD003038-fig-0025" title="">Analysis 10.1</a>), only piperacillin‐tazobactam was associated with significantly improved survival compared with combination therapy (RR 0.62, 95% CI 0.40 to 0.96, 5 trials, 1093 episodes). In studies including only children, the RR was 0.80 (95% CI 0.29 to 1.64), and in trials including only adults, the RR was 0.90 (95% CI 0.75 to 1.09) (<a href="./references#CD003038-fig-0027" title="">Analysis 11.1</a>). </p> <p>In summary, monotherapy was associated with a trend toward improved survival overall and in all subgroups assessed. </p> </section> <section id="CD003038-sec-0057"> <h4 class="title">Infection related mortality and treatment failure</h4> <p>Infection related mortality was reported in 41 trials (<a href="./references#CD003038-fig-0005" title="">Analysis 1.2</a>). No deaths related to infection were reported in nine trials (which did not contribute to the meta‐analysis). Monotherapy was associated with a significantly lower rate of infection related mortality compared with combination therapy (RR 0.80, 95% CI 0.64 to 0.99). Results were similar for trials comparing same and different beta‐lactams. The number of participants needed to treat with monotherapy to prevent one death related to infection was 95 participants, but 95% CIs were large (49 to 1241 participants). </p> <p>Studies performed in recent years based their definitions for treatment success and failure on recommendations of the Immuncompromised Host Society (<a href="./references#CD003038-bbs2-0101" title="Anonymous . From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. Journal of Infectious Diseases1990;161(3):397‐401. ">Consensus 1990</a>). Treatment failure reported here is the inverse of "success without modification". It should be noted that we defined <i>treatment failure</i> more broadly in our protocol as death, lack of clinical improvement or any modification of the assigned empirical antibiotic treatment (see earlier, outcomes). Death judged as unrelated to infection was not included in the consensus definitions for failure. Thus other than infection related deaths, treatment failure reflected mainly treatment modifications in trials that were open‐label in the vast majority. </p> <p>In trials comparing the same beta‐lactam, a significant advantage was seen with combination therapy (RR 1.11, 95% CI 1.02 to 1.20) with minor heterogeneity (I<sup>2</sup> = 12%). In trials comparing different beta‐lactams, a significant advantage was observed with beta‐lactam monotherapy (RR 0.92, 95% CI 0.88 to 0.97, I<sup>2</sup> = 16%) (<a href="./references#CD003038-fig-0006" title="">Analysis 1.3</a>). Results diverged for trials comparing same and different beta‐lactams with regard to treatment failure; therefore these data were not pooled for the main and all subsequent analyses of treatment failure. </p> <p>Subgroup analyses for trials comparing the same beta‐lactams (<a href="./references#CD003038-fig-0014" title="">Analysis 4.2</a>; <a href="./references#CD003038-fig-0016" title="">Analysis 5.2</a>; <a href="./references#CD003038-fig-0018" title="">Analysis 6.2</a>; <a href="./references#CD003038-fig-0020" title="">Analysis 7.2</a>; <a href="./references#CD003038-fig-0022" title="">Analysis 8.2</a>; <a href="./references#CD003038-fig-0024" title="">Analysis 9.2</a>) demonstrated significant differences in favour of combination therapy for patients with Gram‐negative infection (RR 1.34) and severe neutropenia (RR 1.48). No significant differences were observed for the subgroups of participants with any microbiologically documented infection, <i>Pseudomonas aeruginosa</i> infection, bacteraemia and haematological cancer. No specific beta‐lactam monotherapy was associated with increased risk for failure (<a href="./references#CD003038-fig-0026" title="">Analysis 10.2</a>). All subgroup analyses for trials comparing the same beta‐lactam were limited by the paucity of trials and participants included. </p> <p>Similar subgroup analyses for trials comparing different beta‐lactams showed that the significant advantage associated with monotherapy persisted in all tested subgroups, except for cases of documented <i>Pseudomonas aeruginosa</i> infection, severe neutropenia and haematological cancer. Similar RRs in favour of monotherapy were observed with the different specific beta‐lactams. </p> <p>No correlation was noted between rates of treatment failure and all cause or infection related mortality in these studies (r = 0.27, P = 0.11, 38 trials, and r = 0.21, P = 0.27, 30 trials, respectively). As expected, infection related mortality was significantly correlated with all cause mortality (r = 0.63, P &lt; 0.001, 29 trials). No significant correlation was noted between publication year and the RRs for mortality or treatment failure. </p> </section> <section id="CD003038-sec-0058"> <h4 class="title">Super‐infections</h4> <p>Twenty‐nine trials, including 4961 episodes, reported on the development of bacterial super infections during and after antibiotic treatment (<a href="./references#CD003038-fig-0007" title="">Analysis 2.1</a>), and 20 trials, including 3437 episodes, reported on fungal super infections (<a href="./references#CD003038-fig-0008" title="">Analysis 2.2</a>). Equivalence was demonstrated with regard to bacterial super infections (RR 1.02, 95% CI 0.87 to 1.19). Fungal super infections developed more frequently in the combination treatment group (RR 0.70, 95% CI 0.49 to 1.00). Data concerning resistant colonisation were scarce. Five trials supplied data regarding any colonisation (<a href="./references#CD003038-bbs2-0004" title="AlanisA , RehmS , WeinsteinAJ . Comparative efficacy and toxicity of moxalactam and the combination of nafcillin and tobramycin in febrile granulocytopenic patients. Cleveland Clinic Quarterly1983;50(4):385‐95. ">Alanis 1983</a>; <a href="./references#CD003038-bbs2-0013" title="CornelissenJJ , deGraeffA , VerdonckLF , BrangerT , Rozenberg‐ArskaM , VerhoefJ , et al. Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients. Antimicrobial Agents and Chemotherapy1992;36(4):801‐7. ">Cornelissen 1992</a>; <a href="./references#CD003038-bbs2-0023" title="ErjavecZ , deVries HospersHG , vanKampH , van derWaaijD , HalieMR , DaenenSM . Comparison of imipenem versus cefuroxime plus tobramycin as empirical therapy for febrile granulocytopenic patients and efficacy of vancomycin and aztreonam in case of failure. Scandinavian Journal of Infectious Diseases1994;26(5):585‐95. ">Erjavec 1994</a>; <a href="./references#CD003038-bbs2-0039" title="KojimaA , ShinkaiT , SoejimaY , OkamotoH , EguchiK , SasakiY , et al. A randomized prospective study of imipenem‐cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. American Journal of Clinicial Oncology1994;17(5):400‐4. ">Kojima 1994</a>; <a href="./references#CD003038-bbs2-0047" title="NorrbySR , VandercamB , LouieT , RundeV , NorbergB , AnnikoM , et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multiclinic study. Scandinavian Journal of Infectious Diseases Supplement1987;52:65‐78. VandercamB , EzzeddineH , AgaliotisD , GalaJL , GigiJ , WautersG , et al. Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies. Acta Clinica Belgica1989;44(2):99‐109. ">Norrby 1987</a>), and comparison of colonisation with resistant Gram‐negative bacteria was possible in only two studies (<a href="./references#CD003038-bbs2-0013" title="CornelissenJJ , deGraeffA , VerdonckLF , BrangerT , Rozenberg‐ArskaM , VerhoefJ , et al. Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients. Antimicrobial Agents and Chemotherapy1992;36(4):801‐7. ">Cornelissen 1992</a>; <a href="./references#CD003038-bbs2-0047" title="NorrbySR , VandercamB , LouieT , RundeV , NorbergB , AnnikoM , et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multiclinic study. Scandinavian Journal of Infectious Diseases Supplement1987;52:65‐78. VandercamB , EzzeddineH , AgaliotisD , GalaJL , GigiJ , WautersG , et al. Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies. Acta Clinica Belgica1989;44(2):99‐109. ">Norrby 1987</a>). In these studies, resistant Gram‐negative bacteria were detected in 5 of 152 participants in the monotherapy group versus 1 of 152 in the combination group. Notably, none of the newer trials included in the updated review performed surveillance cultures, nor did they report on colonisation with resistant bacteria. </p> </section> <section id="CD003038-sec-0059"> <h4 class="title">Adverse events</h4> <p>Adverse events were significantly more frequent in the combination treatment group. The difference was most remarkable when development of renal failure was compared (RR 0.45, 95% CI 0.35 to 0.57) for any nephrotoxicity (<a href="./references#CD003038-fig-0011" title="">Analysis 3.3</a>) and (RR 0.16, 95% CI 0.05 to 0.49) for severe nephrotoxicity (<a href="./references#CD003038-fig-0012" title="">Analysis 3.4</a>). Nephrotoxicity was more common in the combination therapy than in the monotherapy arm also in studies using a once‐daily dosing regimen for the aminoglycoside (RR 0.31, 95% CI 0.15 to 0.63, 8 trials, 1707 participants). In assessment of any adverse effect in all trials and in studies grouped by their monotherapy (<a href="./references#CD003038-fig-0009" title="">Analysis 3.1</a>), an advantage of monotherapy was seen overall (RR 0.87, 95% CI 0.81 to 0.94), and with ceftazidime monotherapy (RR 0.64, 95% CI 0.53 to 0.76). Likewise, discontinuation of study medication due to adverse events occurred more often in the combination group (<a href="./references#CD003038-fig-0010" title="">Analysis 3.2</a>) (RR 0.61, 95% CI 0.40 to 0.93). The number needed to harm with combination therapy was 34 participants (95% CI, 20 to 104) with regard to any adverse event and 31 participants (95% CI, 24 to 42) with regard to nephrotoxicity. </p> </section> <section id="CD003038-sec-0060"> <h4 class="title">Other outcomes</h4> <p>Duration of hospital stay was non‐significantly shorter in the monotherapy group in each of the four trials that reported this outcome: mean 24.8 days (standard deviation (SD) 21 to 31) versus 27.3 days (SD 23 to 56) (<a href="./references#CD003038-bbs2-0015" title="De laCamaraR , FigueraA , SuredaA , HermidaG , VergeG , OlallaI , et al. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. Haematologica1997;82(6):668‐75. ">De la Camara 1997</a>, data availed through personal correspondence), median 8.6 ± 4 versus 11.8 ± 5.6 (<a href="./references#CD003038-bbs2-0012" title="CorapciogluF , SarperN . Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatric Hematologic Oncology2005;22(1):59‐70. ">Corapcioglu 2005</a>), mean 9.96 versus 11.93 days (<a href="./references#CD003038-bbs2-0034" title="JimenoA , ArcedianoA , BazaresS , AmadorML , Gonzalez‐CortijoL , CiruelosE , et al. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia. Clinical Transplantation and Oncology2006;8(12):889‐95. JimenoA , ArcedianoA , GomezC , BezaresS , CastellanoD , Paz‐AresL , et al. Randomized study of cefepime versus ceftazidime plus amikacin in febrile neutropenic patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS). Proceedings of the Annual Meeting of the American Society of Clinical Oncology; Abstract 3387. 2003. ">Jimeno 2006</a>) and mean 12.6 ± 5.3 versus 10.6 ± 4.7 (<a href="./references#CD003038-bbs2-0070" title="YildirimI , AytacS , CeyhanM , CetinM , TuncerM , CengizAB , et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. Pediatric Hematology and Oncology2008;25:291‐9. ">Yildirim 2008</a>) for monotherapy versus combination therapy, respectively. The data were not pooled because variable reporting measures were used. </p> </section> <section id="CD003038-sec-0061"> <h4 class="title">Selection bias</h4> <p>Funnel plot analyses were undertaken for the two main comparisons: failure and mortality. The funnel plot for mortality was symmetrical (<a href="#CD003038-fig-0001">Figure 1</a>). The funnel plots for trials comparing same and different beta‐lactams for failure were separated. Among trials comparing the same beta‐lactam, the funnel plot was approximately symmetrical (<a href="#CD003038-fig-0002">Figure 2</a>); among trials comparing different beta‐lactams, an indication that small trials favouring combination therapy are missing may be present (<a href="#CD003038-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD003038-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="All cause mortality." data-id="CD003038-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>All cause mortality.</p> </div> </div> </div> <div class="figure" id="CD003038-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Failure‐same BL." data-id="CD003038-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Failure‐same BL.</p> </div> </div> </div> <div class="figure" id="CD003038-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Failure‐different BL." data-id="CD003038-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Failure‐different BL.</p> </div> </div> </div> </section> <section id="CD003038-sec-0062"> <h4 class="title">Sensitivity analyses</h4> <p>Sensitivity analyses were performed for the primary outcomes－mortality and failure－to assess the impact of study quality on our results. </p> <p>For mortality, results from studies with adequate allocation concealment (RR 0.88) were similar to results from studies with unclear allocation concealment (RR 0.87; <a href="./references#CD003038-fig-0029" title="">Analysis 12.1</a>), as were results for trials reporting ITT (RR 0.87) versus efficacy analysis (RR 0.88; <a href="./references#CD003038-fig-0030" title="">Analysis 12.2</a>). The effect size was smaller in trials assessing episodes (RR 0.90) compared with trials assessing participants (RR 0.84), although the 95% CI overlapped (<a href="./references#CD003038-fig-0031" title="">Analysis 12.3</a>). Small and large trials provided similar results, with no study size effect for mortality (comparison 12.5). Unpublished trials and those published only in conference proceedings showed no advantage of monotherapy (RR 1.07, 95% CI 1.07 to 0.72 to 1.59), and trials published in peer reviewed journals showed an advantage of monotherapy (RR 0.84, 95% CI 0.71 to 1.00) (<a href="./references#CD003038-fig-0032" title="">Analysis 12.4</a>). </p> <p>For failure among trials comparing the same beta‐lactams, no significant differences in the pooled effect estimate were observed for the different methodological measures assessed. In an ITT analysis counting all dropouts as failures, the advantage of combination therapy decreased (RR 1.07; <a href="./references#CD003038-fig-0036" title="">Analysis 12.8</a>). Analysis by episodes was associated with a larger effect estimate in favour of combination therapy (RR 1.16; <a href="./references#CD003038-fig-0038" title="">Analysis 12.10</a>). The only double‐blinded trial showed similar results for combination therapy versus monotherapy (<a href="./references#CD003038-bbs2-0016" title="DelFaveroA , MenichettiF , MartinoP , BucaneveG , MicozziA , GentileG , et al. A multicenter, double‐blind, placebo‐controlled trial comparing piperacillin‐tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clinical Infectious Diseases2001;33(8):1295‐301. DelFaveroA , MicozziA , BucaneveG , MartinoP . Double‐blind, randomised, clinical trial comparing monotherapy with piperacillin‐tazobactam vs piperacillin‐tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract No. 1092. 1999. MicozziA , BucaneveG , MenichettiF , MartinoP , DelFaveroA , G.I.M.E.M.A.Infection Program. Double blind, randomized, clinical trial comparing monotherapy with piperacillin‐tazobactam versus piperacillin‐tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients.. Supportive Care in Cancer2000;8 Suppl:160, Abstract 63. ">Del Favero 2001</a>, <a href="./references#CD003038-fig-0039" title="">Analysis 12.11</a>). </p> <p>Among trials comparing different beta‐lactams, adequate allocation concealment was associated with a smaller effect estimate in favour of monotherapy than was seen with unclear methods (RR 0.94 versus RR 0.87, respectively; <a href="./references#CD003038-fig-0034" title="">Analysis 12.6</a>). ITT analysis in the publication was associated with a smaller effect estimate than was seen with efficacy analysis (RR 0.80, 95% CI 0.71 to 0.91 versus RR 0.95, 95% CI 0.88 to 1.01, respectively; <a href="./references#CD003038-fig-0035" title="">Analysis 12.7</a>), and an ITT analysis assuming that all dropouts were failures did not alter results significantly (RR 0.92, 95% CI 0.86 to 0.97; <a href="./references#CD003038-fig-0036" title="">Analysis 12.8</a>). Analysis by episodes was associated with a smaller effect estimate than analysis by participants (RR 0.95 versus RR 0.89; <a href="./references#CD003038-fig-0038" title="">Analysis 12.10</a>). Smaller trials were associated with a significantly larger effect estimate than was noted in the bigger trials (RR 0.75, 95% CI 0.67 to 0.84 versus RR 0.98, 95% CI 0.92 to 1.03; <a href="./references#CD003038-fig-0037" title="">Analysis 12.9</a>), pointing at the same small studies for effects observed in the corresponding funnel plot analysis (<a href="#CD003038-fig-0003">Figure 3</a>). No advantage was seen with monotherapy in double‐blind trials (<a href="./references#CD003038-fig-0039" title="">Analysis 12.11</a>). </p> <p>For trials comparing same and different beta‐lactams, unpublished trials showed no difference between monotherapy and combination therapy, but published trials showed a significant difference favouring combination therapy for trials comparing the same beta‐lactams, and favouring monotherapy for trials comparing different beta‐lactams (<a href="./references#CD003038-fig-0040" title="">Analysis 12.12</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003038-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003038-sec-0063"></div> <p>Seventy one trials that included more than 10,000 participants were analysed to compare beta‐lactam monotherapy with beta‐lactam‐aminoglycoside combination therapy for the empirical treatment of febrile neutropenic cancer patients. The same beta‐lactam was compared in 16 trials, but all other trials compared a broad‐spectrum beta‐lactam with a narrower‐spectrum beta‐lactam combined with an aminoglycoside. Most of the participants included in these trials were haematological cancer patients. We assessed all cause mortality as the primary outcome. </p> <p>Monotherapy was associated with a statistically non‐significant lower all cause mortality rate at end of follow‐up (30 days) (RR 0.87, 95% CI 0.75 to 1.02). Results for trials comparing same and different beta‐lactams were similar. Appropriate trial methods (adequate allocation concealment, ITT analysis and analysis by participants) were associated with similar effect estimates in favour of monotherapy, and no small studies effect was observed. Mortality attributed in the primary studies to infection was significantly lower with monotherapy (RR 0.80, 95% CI 0.64 to 0.99). </p> <p>Treatment failure was assessed as the primary outcome in all included trials. By definition, its main addition on the rather subjective outcome of infection related mortality is treatment modifications (<a href="./references#CD003038-bbs2-0101" title="Anonymous . From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. Journal of Infectious Diseases1990;161(3):397‐401. ">Consensus 1990</a>). Among trials comparing the same beta‐lactams, treatment failure was significantly more frequent with monotherapy. This difference likely reflects mainly physicians' tendency for treatment modifications in open trials comparing one antibiotic regimen with a broader‐spectrum regimen. Among trials comparing different beta‐lactams, a significant advantage was seen with monotherapy. Adequate trial methods were associated with smaller effect estimates for both 'same' and 'different' comparisons. Notably, in the single double‐blind trial comparing the same beta‐lactams, failure was equal with combination treatment and with monotherapy, and in three double‐blind trials assessing different beta‐lactams, the RRs were in the opposite direction compared with those in the other trials. We detected a small studies effect for trials comparing different beta‐lactams. This may reflect a publication bias related to trials that assessed a newer monotherapy without showing its advantage. </p> <p>Bacterial super infections occurred with equal frequency with monotherapy and combination therapy. Fungal super‐infections were more common with combination therapy. All adverse events were more common with combination therapy, with a highly significant difference for nephrotoxicity. The pooled effect estimate translated to a number needed to harm of 34 participants (95% CI 20 to 104 participants). </p> <p>To explain the advantage of monotherapy with regard to all cause mortality, several of the secondary outcomes may be used. Infection related mortality was significantly lower with monotherapy, and fungal super infections occurred more frequently with combination treatment. Fungal infections developing during neutropenia are highly lethal (<a href="./references#CD003038-bbs2-0114" title="LinSJ , SchranzJ , TeutschSM . Aspergillosis case‐fatality rate: systematic review of the literature. Clinical Infectious Diseases2001;32:358‐66. ">Lin 2001</a>). Thus, the improvement in survival may indeed be infection related. On the other hand, nephrotoxicity associated with combination therapy is a risk factor for subsequent adverse outcomes. Given these results and those of the methodological quality assessment, it is likely that the both mechanisms contribute to an unbiased advantage in overall survival with monotherapy. </p> <p>Several hypotheses underlie the use of beta‐lactam‐aminoglycoside combination therapy for patients with neutropenia and suspected infection. Synergism is usually claimed as the major reason for combination therapy. Synergism was assessed most directly in trials comparing the same beta‐lactam. We did not detect the beneficial effects of synergism. A wider spectrum of coverage may be the incentive for the addition of an aminoglycoside depending on local patterns of resistance. Studies included in the review did not supply enough data to allow determination of whether coverage is indeed improved with combination therapy. However, the efficacy of aminoglycosides alone for the treatment of neutropenic patients is doubtful (<a href="./references#CD003038-bbs2-0099" title="BodeyGP , MiddlemanE , UmsawadiT , RodriguezV . Infections in cancer patients: results with gentamicin sulfate therapy. Cancer1972;29(6):1697‐701. ">Bodey 1972</a>; <a href="./references#CD003038-bbs2-0113" title="KlasterskyJ , GlauserMP , SchimpffSC , ZinnerSH , GayaH . Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrobial Agents and Chemotherapy1986;29(2):263‐70. ">Klastersky 1986</a>); therefore this potential advantage does not seem substantial. Finally, combination therapy is claimed to prevent emergence of resistant pathogens. Development of resistance after antibiotic treatment is difficult to quantify. We intended to extract data regarding colonisation with resistant pathogens following antibiotic treatment, but these data were rarely available. Resistance was therefore indirectly examined through super infections, under the assumption that infection that develops under antibiotic treatment involves resistant pathogens. No difference was noted in the rate of bacterial super infections between monotherapy and combination therapy, and this analysis resulting in an RR close to 1. Fungal super infections developed more frequently with combination therapy, perhaps as a reflection of increased antibiotic spectrum or burden with combination therapy. Thus we could not show an advantage of combination therapy from this aspect. </p> <p>We chose all cause mortality as the primary outcome, rather than treatment failure or infection related mortality, and have drawn our conclusions from the analysis for all cause mortality. Only a small part of the variance in mortality is explained by infection and its treatment; however, appropriate randomisation should ensure similar distribution of non–infection related risk factors for death between the study groups. Infection related mortality may be prone to bias in that the cause of death is difficult to determine in severely ill cancer patients. Moreover, ignoring deaths due to treatment‐related adverse effects and super infections is inappropriate. Early empirical antibiotic treatment is the standard of practice for febrile neutropenic patients because it has been proven to decrease mortality (<a href="./references#CD003038-bbs2-0110" title="HughesWT , ArmstrongD , BodeyGP , BrownAE , EdwardsJE , FeldR , et al. From the Infectious Diseases Society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases1997;25(3):551‐73. ">Hughes 1997</a>; <a href="./references#CD003038-bbs2-0123" title="SchimpffSC . Empiric antibiotic therapy for granulocytopenic cancer patients. American Journal of Medicine1986;80:Suppl 5C:13‐20. ">Schimpff 1986</a>). Survival is indeed the objective when an acute infection is treated in cancer patients. Treatment failure indicates mainly modifications of the initial antibiotic regimen, and possibly a longer time to defervescence. The implications of such an outcome are not clear from the clinical point of view. Finally, deaths are objective, but failures cannot be objective when the trials are open. It is important to note that we could demonstrate in this review that assessing treatment failure is probably inappropriate, because no correlation between failure and mortality could be shown. </p> <p>Our results are congruent with those of several other analyses of beta‐lactam‐aminoglycoside combination therapy versus beta‐lactam monotherapy, showing no advantage associated with combination therapy. We conducted a similar analysis in non‐neutropenic participants with sepsis, showing an advantage of monotherapy in trials comparing different beta‐lactams, and no difference in trials comparison the same beta‐lactam (<a href="./references#CD003038-bbs2-0118" title="PaulM , Benuri‐SilbigerI , Soares‐WeiserK , LeiboviciL . Beta lactam monotherapy versus beta lactam‐aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta‐analysis of randomised trials. BMJ2004;328(7441):668. ">Paul 2004</a>; <a href="./references#CD003038-bbs2-0120" title="PaulM , SilbigerI , GrozinskyS , Soares‐WeiserK , LeiboviciL . Beta lactam antibiotic monotherapy versus beta lactam‐aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD003344.pub2] ">Paul 2006a</a>). In an analysis of all RCTs comparing the same beta‐lactam in the combination and monotherapy arms, in both neutropenic and non‐neutropenic participants, and including semi‐empirical studies, we did not find a significant difference in all cause mortality, but we noted significantly more bacterial super infections and increased renal failure with the addition of aminoglycosides (<a href="./references#CD003038-bbs2-0115" title="MarcusR , PaulM , ElphickH , LeiboviciL . Clinical implications of ‐lactam–aminoglycoside synergism: systematic review of randomised trials. International Journal of Antimicrobial Agents2011;37(6):491‐503. ">Marcus 2011</a>). An analysis focusing on the development of resistance did not find an advantage associated with combination therapy (<a href="./references#CD003038-bbs2-0097" title="BliziotisIA , SamonisG , VardakasKZ , ChrysanthopoulouS , FalagasME . Effect of aminoglycoside and beta‐lactam combination therapy versus beta‐lactam monotherapy on the emergence of antimicrobial resistance: a meta‐analysis of randomized, controlled trials. Clinical Infectious Diseases2005;41(2):149‐58. ">Bliziotis 2005</a>). Finally, an analysis of observational studies focusing on<i>Pseudomonas aeruginosa</i> infection (mainly bacteraemia), a pathogen with special relevance to neutropenic cancer patients, did not find an advantage for combination therapy (<a href="./references#CD003038-bbs2-0127" title="VardakasKZ , TansarliGS , BliziotisIA , FalagasME . β‐Lactam plus aminoglycoside or fluoroquinolone combination versus β‐lactam monotherapy for Pseudomonas aeruginosa infections: a meta‐analysis. International Journal of Antimicrobial Agents2013;41(4):301‐10. ">Vardakas 2013</a>). </p> <p>The major limitations of this review include the lack of complete data concerning mortality (all cause mortality was available for 44 of 71 included trials, 62%) and the paucity of available data regarding specific patient subgroups, such as those with <i>Pseuomonas aeruginosa</i> infection. Other limitations stem from those of the primary studies. Allocation concealment was at low risk of bias in less than 35% of the trials, and nearly all were non‐blinded. Many of the trials did not adhere to the principle of ITT analysis, resulting in incomplete data reporting. Most studies used febrile episodes as the unit of randomisation, although recurrent episodes are not independent for any for the outcomes assessed. Finally, follow‐up did not seem pre‐determined in many of the studies. Reported mortality may have been biased because the time of assessment was not defined in advance. We included trials regardless of their publication status. The differences detected in our review, namely, the advantage of monotherapy with regard to survival and the divergent advantages with regard to failure, existed with larger effect estimates in trials published in peer reviewed journals. The RRs were close to 1 for these outcomes in unpublished trials, mainly conference proceedings. Their inclusion in the meta‐analysis tipped the overall RRs toward equivalence. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD003038-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="All cause mortality." data-id="CD003038-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Failure‐same BL." data-id="CD003038-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Failure‐same BL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Failure‐different BL." data-id="CD003038-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Failure‐different BL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall effectiveness, Outcome 1 All cause mortality." data-id="CD003038-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Overall effectiveness, Outcome 1 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall effectiveness, Outcome 2 Infection‐related mortality." data-id="CD003038-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Overall effectiveness, Outcome 2 Infection‐related mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall effectiveness, Outcome 3 Treatment failure." data-id="CD003038-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Overall effectiveness, Outcome 3 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Superinfections, Outcome 1 Bacterial superinfections." data-id="CD003038-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Superinfections, Outcome 1 Bacterial superinfections.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Superinfections, Outcome 2 Fungal superinfections." data-id="CD003038-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Superinfections, Outcome 2 Fungal superinfections.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 1 Any adverse event (monotherapy)." data-id="CD003038-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 1 Any adverse event (monotherapy).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 2 Discontinuation due to adverse event." data-id="CD003038-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 2 Discontinuation due to adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 3 Any nephrotoxicity ‐ Ag dosing regimen." data-id="CD003038-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 3 Any nephrotoxicity ‐ Ag dosing regimen.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 4 Severe nephrotoxicity ‐ Ag dosing regimen." data-id="CD003038-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 4 Severe nephrotoxicity ‐ Ag dosing regimen.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Documented infections (subgroup analysis), Outcome 1 All cause mortality." data-id="CD003038-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Documented infections (subgroup analysis), Outcome 1 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Documented infections (subgroup analysis), Outcome 2 Treatment failure." data-id="CD003038-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Documented infections (subgroup analysis), Outcome 2 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bacteraemia (subgroup analysis), Outcome 1 All cause mortality." data-id="CD003038-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Bacteraemia (subgroup analysis), Outcome 1 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bacteraemia (subgroup analysis), Outcome 2 Treatment failure." data-id="CD003038-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Bacteraemia (subgroup analysis), Outcome 2 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gram‐negative infections (subgroup analysis), Outcome 1 All cause mortality." data-id="CD003038-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Gram‐negative infections (subgroup analysis), Outcome 1 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gram‐negative infections (subgroup analysis), Outcome 2 Treatment failure." data-id="CD003038-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Gram‐negative infections (subgroup analysis), Outcome 2 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Pseudomonas infections (subgroup analysis), Outcome 1 All cause mortality." data-id="CD003038-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Pseudomonas infections (subgroup analysis), Outcome 1 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Pseudomonas infections (subgroup analysis), Outcome 2 Treatment failure." data-id="CD003038-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Pseudomonas infections (subgroup analysis), Outcome 2 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Haematological cancer patients (subgroup analysis), Outcome 1 All cause mortality." data-id="CD003038-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Haematological cancer patients (subgroup analysis), Outcome 1 All cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Haematological cancer patients (subgroup analysis), Outcome 2 Treatment failure." data-id="CD003038-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Haematological cancer patients (subgroup analysis), Outcome 2 Treatment failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Severe neutropenia (subgroup analysis), Outcome 1 All cause mortality." data-id="CD003038-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Severe neutropenia (subgroup analysis), Outcome 1 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Severe neutropenia (subgroup analysis), Outcome 2 Treatment failure." data-id="CD003038-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Severe neutropenia (subgroup analysis), Outcome 2 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Monotherapy, Outcome 1 All cause mortality." data-id="CD003038-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Monotherapy, Outcome 1 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Monotherapy, Outcome 2 Treatment failure." data-id="CD003038-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Monotherapy, Outcome 2 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Adults vs. children, Outcome 1 All cause mortality." data-id="CD003038-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Adults vs. children, Outcome 1 All cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Adults vs. children, Outcome 2 Treatment failure." data-id="CD003038-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Adults vs. children, Outcome 2 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 1 Allocation concealment (mortality)." data-id="CD003038-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 1 Allocation concealment (mortality). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 2 Intention‐to‐treat vs. efficacy analysis (mortality)." data-id="CD003038-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 2 Intention‐to‐treat vs. efficacy analysis (mortality). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 3 Unit of randomisation (mortality)." data-id="CD003038-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 3 Unit of randomisation (mortality). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 4 Publication status (mortality)." data-id="CD003038-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 4 Publication status (mortality). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 5 Trial size (mortality)." data-id="CD003038-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 5 Trial size (mortality). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 6 Allocation concealment (failure)." data-id="CD003038-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 6 Allocation concealment (failure). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 7 Intention to treat vs. efficacy analysis (failure)." data-id="CD003038-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.7</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 7 Intention to treat vs. efficacy analysis (failure). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 8 Intention to treat vs. efficacy analysis, assuming dropouts=failures (failure)." data-id="CD003038-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.8</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 8 Intention to treat vs. efficacy analysis, assuming dropouts=failures (failure). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 9 Trial size (failure)." data-id="CD003038-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.9</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 9 Trial size (failure). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 10 Unit of randomisation (failure)." data-id="CD003038-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.10</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 10 Unit of randomisation (failure). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 11 Blinding (failure)." data-id="CD003038-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.11</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 11 Blinding (failure).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003038-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/urn:x-wiley:14651858:media:CD003038:CD003038-CMP-012-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_t/tCD003038-CMP-012-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 12 Publication status (failure)." data-id="CD003038-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.12</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (outcome in parenthesis), Outcome 12 Publication status (failure). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/media/CDSR/CD003038/image_n/nCD003038-CMP-012-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003038-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">beta‐lactam monotherapy compared to beta‐lactam‐aminoglycoside combination therapy for Febrile neutropenic cancer patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐lactam monotherapy compared with beta‐lactam‐aminoglycoside combination therapy for febrile neutropenic cancer patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> febrile neutropenic cancer patients.<br/> <b>Settings:</b> <br/> <b>Intervention:</b> beta‐lactam monotherapy.<br/> <b>Comparison:</b> beta‐lactam‐aminoglycoside combination therapy. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Beta‐lactam‐aminoglycoside combination therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Beta‐lactam monotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.87</b> <br/> (0.75 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7186<br/> (44 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> <br/> (62 to 85) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> <br/> (51 to 69) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Any nephrotoxicity ‐ Ag dosing regimen (Copy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> <br/> (0.35 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6608<br/> (39 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (20 to 33) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (10 to 17) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure ‐ same beta‐lactam</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.11</b> <br/> (1.02 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2833<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>449 per 1000</b> <br/> (413 to 485) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>398 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>442 per 1000</b> <br/> (406 to 478) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment failure ‐ different beta‐lactam</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.88 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7736<br/> (55 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>426 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>392 per 1000</b> <br/> (375 to 413) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>432 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>397 per 1000</b> <br/> (380 to 419) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Outcome determined mainly by treatment modifications. Poor correlation with all cause mortality, the ultimate target of treating cancer patients.<br/> <sup>2</sup> Differences decreased with low risk of bias regarding allocation concealment.<br/> <sup>3</sup> Differences in effects between published and unpublished trials.<br/> <sup>4</sup> No explanation was provided.&amp;&amp; </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">beta‐lactam monotherapy compared to beta‐lactam‐aminoglycoside combination therapy for Febrile neutropenic cancer patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/full#CD003038-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall effectiveness</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 same beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.53, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 different beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Infection‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 same beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.43, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 different beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.65, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 same beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [1.02, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 different beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.88, 0.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall effectiveness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Superinfections</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bacterial superinfections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fungal superinfections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.49, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Superinfections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Any adverse event (monotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.81, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 imipenem monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 meropenem monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 ceftazidime monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.53, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 moxalactam monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.51, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 cefepime monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.75, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 other monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.61, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Discontinuation due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4051</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.40, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any nephrotoxicity ‐ Ag dosing regimen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.35, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.15, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Multiple daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.36, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Severe nephrotoxicity ‐ Ag dosing regimen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.05, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.03, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Multiple daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Documented infections (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.56, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 same beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 different beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.82, 0.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Documented infections (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Bacteraemia (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.46, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 same beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.90, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 different beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Bacteraemia (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Gram‐negative infections (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 same beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.03, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 different beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.60, 0.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Gram‐negative infections (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Pseudomonas infections (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.34, 2.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 same beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.90, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 different beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.60, 1.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Pseudomonas infections (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Haematological cancer patients (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.68, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 same beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 different beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Haematological cancer patients (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Severe neutropenia (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.37, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 same beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.12, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 different beta‐lactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Severe neutropenia (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ceftazidime monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 imipenem monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.68, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 meropenem monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.77, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 moxalactam monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.26, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 piperacillin‐tazobactam monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 cefepime monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.61, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 other monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.19, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 same BL ‐ ceftazidime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.94, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 same BL ‐ imipenem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.92, 10.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 same BL ‐ piperacillin‐tazobactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.92, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 same BL ‐ cefepime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.84, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 same BL ‐ other monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.30, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 different BL ‐ ceftazidime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.89, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 different BL ‐ imipenem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 different BL ‐ meropenem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 different BL ‐ moxalactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.60, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 different BL ‐ piperacillin‐tazobactam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.53, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 different BL ‐ cefepime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 different BL ‐ other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.83, 1.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Adults vs. children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.39, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 mixed/ undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.52, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 same BL ‐ children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.95, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 same BL ‐ mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.90, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 same BL ‐ adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.04, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 different BL ‐ children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1086</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 different BL ‐ mixed/ undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 different BL ‐ adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.85, 0.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Adults vs. children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003038-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analysis (outcome in parenthesis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Allocation concealment (mortality) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.73, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.61, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Intention‐to‐treat vs. efficacy analysis (mortality) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 efficacy analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.73, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 intention‐to‐treat analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.66, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Unit of randomisation (mortality) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 patient analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.66, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 episode analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Publication status (mortality) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.75, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 jounal publication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.71, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 other publication or un‐published</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.72, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Trial size (mortality) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 number randomised&gt;median 94p</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.75, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 number randomised&lt;median 94p</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.55, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Allocation concealment (failure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 same beta‐lactam ‐ A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.99, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 same beta‐lactam ‐ B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.99, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 same beta‐lactam ‐ C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.73, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 different beta‐lactam ‐ A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 different beta‐lactam ‐ B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.79, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 different beta‐lactam ‐ C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.48, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Intention to treat vs. efficacy analysis (failure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 same BL ‐ efficacy analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.98, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 same BL ‐ ITT analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 different BL ‐ efficacy analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 different BL ‐ ITT analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.71, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Intention to treat vs. efficacy analysis, assuming dropouts=failures (failure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 same BL ‐ efficacy analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.02, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 same BL ‐ ITT analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.96, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 different BL ‐ efficacy analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.89, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 different BL ‐ ITT analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Trial size (failure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 same BL no. randomised&gt;median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.01, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 same BL no. randomised&lt;median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.94, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 different BL no. randomised&gt;median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 different BL no. randomised&lt;median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.67, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Unit of randomisation (failure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 same beta‐lactam ‐ patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 same beta‐lactam ‐ episode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.04, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 different beta‐lactam ‐ patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.82, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 different beta‐lactam ‐ episode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Blinding (failure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 same beta‐lactam ‐ double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.90, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 same beta‐lactam ‐ other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.04, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 different beta‐lactam ‐ double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.83, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 different beta‐lactam ‐ other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Publication status (failure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 same beta‐lactam ‐ journal publication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.02, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 same beta‐lactam ‐ other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.79, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 different beta‐lactam ‐ journal publication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.86, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 different beta‐lactam ‐ other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analysis (outcome in parenthesis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003038.pub2/references#CD003038-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003038.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003038-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003038-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD003038-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003038-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003038-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003038\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003038\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003038\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003038\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003038\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003038.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003038.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003038.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003038.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003038.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724908704"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003038.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724908708"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003038.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6e4a2e53f4ca',t:'MTc0MDcyNDkwOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 